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Abstract
The Wilms’ tumour antigen 1 (WT1) is a transcription factor which is over-expressed 
in several leukaemias and solid tumours. Currently, there is limited information about 
the expression and immunogenicity of WT1 in prostate cancer. I used 
immunohistochemistry to analyse WT1 expression in prostate cancer samples and 
tetramers to detect WT1-specific T cell responses in the peripheral blood. 39% of 
cancer samples showed nuclear and cytoplasmic staining for WT1, whereas the 
staining of all normal prostate tissue was limited to the cytosol (p<0.03). Furthermore, 
WT1 -specific T cells which bound tetramer were detectable in the peripheral blood of 
20/38 (53%) prostate cancer patients, ex vivo. Although these T cells did not expand 
in 20/20 patients using peptide stimulation with IL2/IL7, a population of WT1-specific 
CTL accumulated in 3/8 patients following culture with IL15.
T cell receptor (TCR) gene transfer is a strategy to circumvent possible impairment of 
autologous T cell responses against tumour associated antigens such as WT1. 
However, exogenous and endogenous TCRs are in competition for CD3 chains, 
which may reduce the expression of the introduced TCR and impair the antigen 
specific function of transduced T cells. I developed an approach to improve the 
expression of exogenous TCR chains by co-transducing TCR genes together with 
the genes encoding the CD3 complex. Transfer of CD3 and TCR genes into primary 
T cells resulted in up to a 5 fold increase in TCR expression and up to a 9 fold 
increase in tetramer binding compared to that seen after transfer of TCR genes 
alone. Furthermore, T cells expressing high levels of TCR/CD3 demonstrated 
increased sensitivity. This data indicates that the efficacy of TCR expression, and the 
effector function of gene modified T cells, is substantially enhanced by the co-transfer 
of CD3 genes.
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Chapter 1: General Introduction
1.1 Tumour immunotherapy
Cancer is a common disease which will affect 1 in 3 people during their lifetime. As 
the population continues to age, the incidence of cancer continues to rise. While 
surgery and radiotherapy are effective treatments for localised disease, a large 
proportion of patients present with metastatic disease. Traditional chemotherapeutic 
agents exert their effects by interfering with cell division and work on the premise that 
cancer cells will be dividing more quickly than healthy cells. Hence, chemotherapy 
also has predictable side effects on dividing cells in the bone marrow, skin, 
gastrointestinal tract epithelium and hair follicles. Although chemotherapy has been 
shown to improve survival in many different tumours, in the vast majority of cases 
chemotherapy for metastatic disease remains a palliative treatment. Thus, the ratio of 
the inherent risks of the treatment versus the potential benefit to patients is always a 
major consideration, given the toxicities associated with conventional treatment.
The focus of current cancer research is on providing targeted anti tumour therapy 
which can distinguish between malignant and normal cells, therefore reducing the 
toxic side effect profile commonly experienced with traditional chemotherapeutic 
agents. Antigen specific immunotherapy is an example of a targeted therapy which 
aims to reduce the risks associated with treatment while increasing the benefit to 
patients.
The goal of tumour immunotherapy is to target tumours by providing either active or 
passive immunity against malignancies. In passive immunotherapy, the effectors of 
the immune response (e.g. antibodies or T cells) are directly transferred into patients. 
Active immunotherapy, of which vaccination is an example, requires the patient to 
mount an immune response against cancer antigens.
Early attempts at cancer immunotherapy focused on cytokines such as interleukin-2 
(IL2) that activate both innate and adaptive immune responses in a non antigen 
specific manner. However, cytokine therapy is associated with significant systemic 
side effects. Advances in scientific knowledge and technology have led to the 
development of antibody and T cell based therapies which utilise the unique 
specificity of immune receptors to target selected antigens on tumour cells. This 
reduces their systemic side effect profile compared to cytokine therapy.
13
1.1.1 Tumour immunosurveillance
The increased incidence of certain tumours in immunosuprressed patients compared 
to age matched controls is well established, for example: non Hodgkin’s lymphoma, 
Kaposi’s sarcoma, cervical carcinoma and skin cancers (1-3). The concept that the 
immune system could play a role in detecting and preventing the development of 
tumours was first described by Erlich in 1909 (4). He proposed the concept that 
spontaneously arising tumours could be recognised and destroyed by cells of the 
immune system. The “cancer immunosurveillance hypothesis” was reintroduced 
decades later by Burnet and Thomas. They suggested that the mammalian immune 
system had evolved to recognise mutations which contribute towards the malignant 
phenotype of cancer cells, and that the immune system was responsible for the 
destruction of malignancies in mammals that do not present clinically (5-7). However, 
the experiments performed to investigate the hypothesis remained inconclusive. 
More recently, new experimental models were developed to support the concept of 
immunosurveillance.
It has been shown that there is an increased incidence of spontaneous and 
carcinogen induced tumours in several murine models where elements of the 
immune system are defective (8). The definitive experiments were performed in Rag 
deficient mice (Rag-/-), which do not produce any T or B lymphocytes. This model 
was used to study the effect of immunodeficiency on tumour development. It was 
shown that Rag-/- mice developed a greater number of tumours more quickly and 
more frequently in response to a chemical carcinogen (MCA) than wild-type control 
mice. IFNy insensitive mice (lacking either the IFNy receptor or STAT1, a 
transcription factor which plays a crucial role in IFNa/p and IFNy receptor signalling) 
also developed more tumours than wild type controls. The same group also 
demonstrated that spontaneous adenocarcinoma development was significantly 
more frequent in Rag-/- mice and in Rag-/- mice which also had an IFN signalling 
deficit, compared with wild type mice (9). This data supported the idea that the 
immune system can recognise and destroy cancer cells based on differences 
between normal and cancerous cells.
However, this concept is at odds with the fact that cancers commonly develop in 
immunocompetent hosts. This may be a result of immune surveillance putting 
selective pressure on tumour cells to develop ways of evading the immune system 
and becoming less immunogenic, a process described as cancer immunoediting 
(8:10).
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1.1.2 Cancer immunoediting
Normal cells are under tight regulation of cell division, growth and controlled cell 
death (apoptosis). By developing mutations in the tumour suppressor genes or 
oncogenes which control these processes, normal cells develop a malignant 
phenotype and hence the ability to divide and grow inappropriately. The hallmarks of 
cancer are: self sufficiency in growth signals, ignoring growth inhibition signals, 
evasion of apoptosis, replicative potential, angiogenesis and tissue invasion (11). It 
has been suggested that immune evasion is the 7th hallmark of cancer (8). This has 
implications for immunotherapy, as tumours that develop will, by definition, have 
escaped control by naturally occurring immune responses.
The process of cancer immunoediting has been proposed to involve 3 phases: 
elimination, equilibrium and escape. The elimination phase involves transformed 
cells being recognised and killed by cells of both the innate and adaptive immune 
systems. The equilibrium phase describes the balance between tumour cell killing 
and survival, resulting in the tumour being contained, but not eliminated. During this 
phase there is selective pressure on tumour cells to develop ways of evading or 
inhibiting immune responses, resulting in the growth of tumour escape variants. 
There are a number of mechanisms by which tumours can become less 
immunogenic. These include the loss of target antigen expression or downregulation 
of MHC Class 1 molecules, the secretion of immunosuppressive cytokines such as 
IL-10 and TGF(3.
However, the immunosurveillance theory remains controversial. Using a murine 
sporadic tumour model, Willimsky and Blankenstein demonstrated that although 
specific immune responses against developing tumours did arise, they did not curb 
the tumour’s growth, and that in fact the sporadic tumours induced T cell tolerance. 
They also showed that the tumours which developed in the presence of a normal 
immune system remained immunogenic and were not escape variants (12). Thus, in 
the absence of consistently reproducible data supporting it, the concepts of 
immunosurveillance and immunoediting continue to be contentious topics for 
immunologists.
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1.2 Immunotherapy and the cells of the immune system
The immune system can be divided into the innate and adaptive immune systems, 
both of which can be manipulated for cancer immunotherapy. I will deal with each in 
turn.
1.2.1 Innate immune system
The innate immune system is highly conserved between species and forms a crucial 
first line of defence against infection. It consists mainly of myeloid lineage cells: 
macrophages, neutrophils, eosinophils and mast cells, in addition to natural killer 
(NK) cells, dendritic cells (DC) and the complement pathway. Once activated, cells of 
the innate immune system can kill their targets or secrete cytokines to recruit other 
effectors of the innate and adaptive immune systems to an infected area.
The innate immune system tends to recognise targets commonly found on many 
pathogens, but distinguishable from host molecules: pathogen-associated molecular 
patterns (PAMPs). Toll like receptors (TLR) are a type of pattern recognition receptor 
(PRR) present on many cells of the innate immune system. They form a receptor 
superfamily with the lnterleukin-1 receptors and recognise a range of PAMPs such as 
bacterial or viral DNA, lipopolysaccharide (LPS), which is a component of Gram 
negative bacterial cell walls, and mannose -  a carbohydrate which forms part of the 
cell wall of many pathogens. TLR ligands have been successfully used as 
immunomodulators in preclinical and clinical trials. For example, imiquimod, a 
TLR7/8 ligand, has been shown to be effective in the treatment of basal cell 
carcinoma in a randomized, blinded, multi-centre phase III clinical trial (13). 
Melanoma patients vaccinated with a melanoma antigen plus a synthetic TLR-9 
analogue exhibited melan A specific T cell responses an order of magnitude higher 
than those vaccinated in the absence of the TLR ligand (14).
1.3 The adaptive immune system
The adaptive immune system is common to vertebrates and is thought to have 
evolved in order to deal with viral infections. It is antigen specific, the unique 
specificity being conferred by the T or B cell surface receptor, and also results in the 
formation of a memory response. Antigen specific immunotherapy seeks to direct T 
or B cell receptors (antibodies) against tumour antigens, the aim being that targeted 
therapy should reduce the side effect profile seen with conventional therapy.
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Widespread clinical success has been seen with monoclonal antibodies directed 
against a number of targets including HER2, CD20, vascular endothelial growth 
factor (VEGF) and epidermal growth factor receptors (EGFR). This class of cancer 
therapeutics continues to grow rapidly, with a far less toxic side effect profile than 
conventional chemotherapy and radiotherapy (15-19).
However, antibody therapy has a number of limitations. Firstly, since a memory 
response is not generated, repeated antibody infusions are required. Secondly, 
because some monoclonal antibodies retain a small murine component, they are 
themselves potentially immunogenic, which may cause problems with repeated 
administration. Thirdly, antibodies can only recognise specific proteins which are 
present on the cell surface, which limits the range of available targets. Intracellular 
proteins are broken down into a large number of peptides, which are expressed on 
the cell surface in association with a major histocompatibility molecule (MHC). These 
peptide-MHC complexes are recognised by the T cell receptor (TCR), which is able 
to recognise a far wider range of antigens than antibodies, and therefore a much 
larger number of potential immunotherapy targets.
1.3.1 T cell overview
T lymphocytes originate in the bone marrow and differentiate in the thymus. 95% of T 
cells express a T cell receptor (TCR) composed of an a and a p chain. a(3 T cells can 
be further subdivided according to expression of the co-receptors CD4 or CD8. CD8 
T cells recognise peptides derived from intracellular proteins presented in the context 
of MHC Class I molecules and are able to kill infected cells and tumour cells. CD8 T 
cells are subdivided into Tc1 and Tc2 cells depending on their cytokine secretion 
profile. CD4 cells recognise peptides from exogenous proteins presented in the 
context of MHC Class II molecules, and can also be further sub-classified according 
to the cytokines they secrete.
Approximately 5% of T cells express a TCR comprised of a gamma and a delta 
chain: y5 T cells, of which there are several subsets. They have been described as a 
bridge between the innate and adaptive immune systems, and encompass features 
of both. Similarly to a(3 T cells, a subset of yS T cells can develop in the thymus, 
rearrange TCR genes to produce junctional diversity and are found in the lymphoid 
tissue (20). In addition, y5 T cells can be described as either naive (CD45RA) or 
memory (CD45RO) in terms of both function and phenotype (21 ;22).
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A second subset of y6 T cells are most prevalent in epithelial tissues such as the gut, 
lung and reproductive tract, where they display receptors of limited diversity. Unlike 
ap T cells, y6 T cells do not generally recognise peptide antigens presented by MHC 
molecules. y5 T cells can recognise self proteins which are upregulated as a result of 
infection or cellular stress, such as heat shock proteins, MIC-A and MIC-B (23). y6 T 
cells may also act via pattern recognition receptors similar to those seen on cells of 
the innate immune system, and have been reported to express TLR2 and NKG2D 
(24) Although the range of molecules which activate y5 T cells has not been fully 
characterised, all Vy9A/62 T cells recognize the microbial compound 4-hydroxy-3- 
methyl-but-2-enylprypophosphate (HMB-PP), which is an essential metabolite in 
most pathogenic bacteria.
1.4 Antigen recognition
Whereas B cells recognise intact molecules expressed on the surface of a cell, T 
cells recognise peptides in association with an MHC molecule. One advantage of this 
is that, because the peptides are derived from the cell interior, T cell receptors are 
able to recognise cells infected with a virus even when the virus is not expressing full 
length proteins on the cell surface. Another advantage is that a protein on the cell 
surface may be folded in such a way that certain epitopes are not exposed. Breaking 
a protein into peptide epitopes vastly increases the number of targets available for 
recognition by TCRs. There are separate pathways by which antigens originating 
either inside or outside the cell are processed.
1.4.1 Class I antigen processing pathway
CD8 T cells recognise peptides presented in association with self MHC Class I 
molecules, which are present on all nucleated cells. The MHC Class I molecule is a 
heterodimer consisting of an a chain which is non-covalently linked to a (3- 
microglobulin chain. The a chain consists of three extracellular domains: a1 and a2 
are folded together to form a cleft which forms the peptide binding domain, while a3 
resembles an immunoglobulin constant domain which spans the cell membrane.
The peptides presented by MHC Class I molecules originate in the cell cytoplasm, 
and include viral, bacterial and tumour derived as well as self proteins. It was initially 
thought that the main source of antigenic peptides was the breakdown of proteins at 
the end of their lifespan (25). However, peptides are also produced from the 
breakdown of defective products of protein synthesis (or defective ribosomal 
products: DRiPs) which are the result of mistranslations, misfolding, truncations or 
incorrect post translational modification (26). One advantage of this is that changes in
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intracellular gene expression, for example as a result of viral infection, will rapidly be 
translated into peptide expression on the cell surface (27;28). A large, multicatalytic 
protease complex in the cytoplasm called the proteasome is responsible for cleaving 
proteins into peptides. Proteasomes are highly conserved between species and are 
present in all eukaryotes. They are comprised of 28 subunits which form a cylindrical 
structure: 4 stacked rings each of 7 subunits, with the active sites of the proteolytic 
subunits lining the core of the cylinder. Inhibitors of the proteolytic activity of the 
proteasome inhibit antigen presentation by Class I molecules (29). The main function 
of the proteasome is the ubiquitin-dependent degradation of cytosolic proteins; 
experimentally tagging proteins with ubiquitin results in their peptides being more 
efficiently presented by MHC Class I molecules (30;31).
Heat shock proteins (HSP) are also thought to play an important role in transferring 
peptides from the cytosol onto MHC Class I molecules within the endoplasmic 
reticulum (ER). HSP ordinarily make up approximately 5% of normal intracellular 
proteins, but this figure may increase to over 15% when the cell is under stress (for 
example: at high temperatures). Initial studies on HSP gp96 showed that animals 
which were immunised with gp96 preparations isolated from certain tumours were 
then protected against challenge by the same, but not other, tumours. Subsequent 
studies suggested that this was due to the ability of the gp96 chaperone protein to 
bind to a pool of intracellular peptides. Similar results were observed with two further 
cytoplasmic proteins, HSP70 and HSP90 (32). However, it is not clear whether the 
tumour rejection induced by HSP is peptide specific, or independent of the bound 
peptide and instead mediated by the innate immune system (33). The nature of 
processed peptides that associate with these chaperones is not well understood, nor 
is the role the peptide/chaperones play in the antigen-processing pathway. It remains 
unclear whether these chaperones act as transporters between different steps of the 
antigen-processing pathway (34) or whether they act as peptide sinks (35).
Peptides are loaded onto MHC molecules which are first assembled in the 
endoplasmic reticulum (ER). Since they are only stable with peptide occupying their 
peptide binding groove, a number of chaperone proteins play an important role in 
stabilising MHC molecules until this occurs. During assembly, partially folded MHC 
molecules are bound to the chaperone protein calnexin until the Class I a chain 
associates with (32 microglobulin. The calnexin then dissociates and the MHC 
complex binds to a complex of chaperone proteins including calreticulin, thiol- 
oxidoreductase Erp57 and tapasin, which associates with the transporter associated 
with antigen processing: TAP. TAP consists of a heterodimer formed by TAP1 and
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TAP2, which spans the ER membrane and plays a crucial role in allowing peptides 
from the cytosol to enter the ER lumen. This is an ATP dependent process; TAP is a 
member of the ATP-binding cassette (ABC) transporter family (36). TAP transporter 
proteins most efficiently transport peptides which are 8 to 13 amino acids long: the 
appropriate length to fit in the Class I MHC groove.
Longer peptides which are transported into the ER are then trimmed by the 
endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP). 
This enzyme removes residues from the amino end of peptides which are too long to 
fit into the MHC Class I peptide binding groove. Upon binding of a peptide in the 
MHC groove, the MHC molecule dissociates from its chaperone proteins (the 
TAP:tapasin:catreliculin:Erp57 complex) and is transported to the cell surface (37).
Role of interferons in Class I antigen processing
Interferon production, induced primarily by viral infections, exerts a strong influence 
on the Class I processing pathway by increasing the efficiency of antigen 
presentation through an increase in MHC Class I expression. In addition, while the 
proteasome exists in a constitutive form in all cells, IFNy causes a change in the 
proteasome by inducing expression of subunits b1i, b2i and b5i, which substitute for 
constitutively expressed subunits, resulting in the production of the 
immunoproteasome. This cleaves peptides after hydrophobic residues with increased 
frequency, thus producing peptides with a preferred structure for binding both TAP 
and MHC class I molecules (38-40).
IFNy also induces PA28 a and (3, which make up the PA28 proteasome-activator 
molecule. PA28 is a six or seven membered ring which binds to the ends of the 
cyclindrical proteasome structure, opening up the ends to increase the rate at which 
both proteins enter and peptides can be released. IFN also upregulates the 
endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP). 
In addition, interferons increase the expression of both Class I and Class II MHC 
molecules. IFNy can also induce Class II expression on cells that do not 
constitutively express it (41 ;42)
1.4.2 Class II antigen processing
The MHC Class II molecule is composed of an a and (3 chain; transmembrane 
glycoproteins which are non-covalently linked. The peptide binding domain contains 
the greatest polymorphic diversity and is formed by the a1 and (31 subunits. Class II 
molecules present antigen to CD4 T cells, and are generally found on cells of the
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immune system: thymic stromal cells, T cells in humans, B cells, DCs and 
macrophages. Class II molecules display peptides derived from the cell exterior 
which have been phagocytosed, as well as proteins derived from pathogens which 
replicate within intracellular vesicles. Endocytic vesicles, having become more acidic 
as they progressively move further from the cell exterior, fuse with lysosomes. These 
contain proteases including cathepsins which are activated at low pH and break 
down proteins into peptides which are typically 13-17 amino acids in length (43-45).
Class II molecules are synthesized in the ER where they associate with a trimeric 
MHC Class ll-associated invariant chain complex. This occupies the peptide binding 
groove to prevent peptides within the ER from binding, and also targets Class II 
molecules to the endosomal compartment (46-50). Here the invariant chain is 
cleaved several times by proteases such as cathepsin S to release the Class II 
molecule from the invariant chain, leaving only a short peptide fragment still bound: 
CLIP (class II associated invariant chain peptide).
Specialised Class ll-like molecules within endosomes then catalyse the peptide 
loading of the MHC Class II peptide binding groove. HLA-DM is comprised of an a 
and (3 chain which closely resemble those of Class II molecules, but differs in that it is 
not expressed on the cell surface. HLA-DM binds to MHC Class ILCLIP complexes 
and catalyses the release of CLIP and the binding of antigenic peptides. HLA-DM 
also binds to MHC Class Ikpeptide complexes, removing weakly bound peptides and 
allowing them to be replaced by other peptides. HLA-DM is negatively regulated by a 
further atypical MHC Class II molecule, HLA-DO, which is also found within vesicles 
rather than on the cell surface. HLA-DO binds to HLA-DM and prevents it from 
releasing CLIP from Class II molecules, thus preventing peptides from binding. In 
inflammation, the release of IFN-y from NK cells and T cells upregulates expression 
of HLA-DM, but not its negative regulator, HLA-DO, the net result of which is 
increased antigen presentation (51-53).
1.4.3 Cross presentation
In the main, antigens within the cytosol are presented by Class I molecules to CD8 T 
cells and antigens from outside the cells are presented by Class II molecules to CD4 
cells. The exception to this is when antigen presenting cells take up external antigen, 
yet present it on Class I molecules: cross presentation (54;55). Cross presentation is 
required to induce a CD8 T cell response against a virus which does not infect 
professional antigen presenting cells. The mechanism has yet to be elucidated, but 
may involve antigens being transferred from phagosomes into the cytosol before
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cleavage by cytosolic proteasomes and transport into the ER via TAP (56-58) Cross 
presentation has been demonstrated by a number of groups who have suggested 
that it plays an important role in presenting antigens derived from tumours as well as 
viruses (59;60)
1.5 Choosing a target for cancer immunotherapy
The ideal anti-cancer agent would specifically target tumours without having 
deleterious effects on normal cells. An appropriate antigen target for immunotherapy 
is therefore one which is either only expressed on tumours, or expressed at very high 
levels relative to normal tissues. In addition, those cancers which develop in 
association with chronic viral infections may express viral antigens.
In theory, one would expect tumour specific antigens (TSA) to be better targets, since 
they are only expressed on cancer cells. TSA may arise as a result of gene 
mutations and translocations, such as the bcr/abl tyrosine kinase seen in chronic 
myeloid leukaemia (61) or p-catenin in melanoma (62). However, a drawback of 
using TSA as targets is that if patients harbour different mutations, they would need 
individual therapies recognising each individual target. A good target for cancer 
immunotherapy is therefore also one which is present on the tumours of multiple 
individuals.
TSA are often not well recognised by T cells. This is due to the peptide products of 
TSA being poorly presented by host Class I molecules. This may be because they 
have a poor binding affinity for self MHC molecules, in which case they will be out- 
competed by host self peptides for association with MHC molecules and presentation 
on the cell surface.
The majority of cancer immunotherapy targets identified to date are normal cellular 
proteins which are expressed at elevated levels in tumours: tumour associated 
antigens (TAA). The aim is to exploit the difference in the surface expression level of 
the target antigen on tumours compared to that on normal tissue. Expression in 
normal tissues may also be restricted, as is the case with testis cancer antigens. 
Since TAA are non mutated proteins they are not specific to individual patients, 
therefore strategies targeting a specific TAA can be used for all patients whose 
cancer over-expresses the target antigen. For example, MART-1 is over-expressd on 
the majority of melanomas and the Wilm’s Tumour Antigen 1 (WT1) is over 
expressed on a number of different tumours including cancers of the colon, breast, 
lung and ovary. An immunotherapeutic strategy which targets WT1 can therefore be 
used against multiple tumour types.
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TAA can be broadly divided into three groups, the first of which is the cancer testes 
antigens, which are usually only expressed by the germline cells of the testes. 
Examples include MAGE-1 and NY-ESO, which are upregulated in a number of 
malignancies including melanoma, breast and oesophageal cancer (63;64). These 
were originally thought to be tumour specific, since germline cells do not express 
MHC Class I and therefore would not express these antigens to the immune system. 
However, MAGE-1 and NY-ESO have been found to be expressed by medullary 
thymic epithelial cells, albeit at lower levels than in the testis, meaning that they are 
still likely to be subject to tolerance mechanisms (65).
The next group consists of the differentiation antigens. These are tissue specific 
antigens which are expressed by normal cells, but over-expressed when these cells 
become malignant. The melanoma differentiation antigens are the best described 
antigens of this group and include MART-1, tyrosinase and gp100, whose expression 
is limited to normal melanocytes and malignant melanomas. (66-68) Another 
example would be the prostate specific antigen (PSA), which is expressed on normal 
prostate cells and is over-expressed in prostate cancer.
The third TAA group consists of antigens which are expressed in a range of normal 
tissues, but which are over-expressed in malignant cells. Rather than being tissue 
specific, these TAA are expressed by a wide range of tissues and therefore 
malignancies. Examples include proteins derived from HER2/neu, cyclin d1, muc1 
and telomerase reverse transcriptase. Some TAA are expressed in the majority of 
normal cells, such as p53 and mdm2, while others, such as WT1, have a limited 
expression pattern in normal tissue. The great advantage of using this group of 
targets for immunotherapy is that if multiple tumour types express the same target, a 
greater number of patients could potentially benefit.
However, there are two significant drawbacks to using TAA as targets for 
immunotherapy. The first is that tolerance mechanisms may affect the avidity of 
immune responses generated against them. The second is the risk of auto-immune 
damage to healthy tissues which also express the self antigen. I will discuss both of 
these issues in more detail below.
1.5.1 TAA and tolerance
Tolerance mechanisms exist to prevent autoimmunity. Potentially harmful, self­
reactive T cells are deleted or rendered unresponsive. Tolerance can either be 
central, in the thymus, or peripheral.
23
1.5.2 Central tolerance
During normal T cell development, immature T cell precursors from the bone marrow 
enter the thymus where they mature and proceed to a two stage selection process. 
Positive selection takes place in the cortex of the thymus. TCRs, having been 
generated by a complex process of gene rearrangement, are then ‘tested’ against 
thymic cortical epithelial cells (which express MHC Class I and II molecules) to 
ensure that T cells which proceed are capable of recognising peptides in association 
with self MHC. Approximately 90% of T cells entering the thymus express a TCR 
which does not interact with self MHC, and subsequently die by neglect (69;70).
The positively selected cells are then ‘tested’ again against thymic antigen presenting 
cells in the medulla which present self peptides. T cells which recognise self 
peptide/MHC combinations with high avidity - and would therefore potentially be 
autoreactive -  are induced to undergo apoptosis (71). Approximately half of all T 
cells which are positively selected are then deleted by this process of clonal deletion, 
or negative selection (72).
However, not all self peptides are naturally presented by thymic cells, so a 
mechanism exists to ensure that T cells which recognise peripherally expressed self 
antigens with high avidity are also subject to negative selection. The autoimmune 
regulator (AIRE) transcription factor controls the expression of peripheral tissue 
genes in thymic medullary cells. Deletion of AIRE is associated with reduced 
transcription of peripheral antigen genes and the development of autoimmune 
disease, highlighting the importance of central tolerance in preventing autoimmunity. 
(73-75).
The combination of positive selection and negative selection ensures that the T cells 
which leave the thymus are able to recognise self MHC, but not self peptides with 
high avidity. However, central tolerance is incomplete, as self reactive T cells can be 
found in the periphery. Studies have shown that T cells can escape central tolerance 
by downregulating co-receptors or by expressing two TCRs simultaneously, and T 
cells which recognise self antigens with low avidity can also escape central tolerance 
(76-78). A consequence of this for tumour immunology is that only T cells which 
recognise TAA with low avidity will be allowed to persist in the circulation, and their 
low avidity may limit their ability to kill tumour cells.
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1.5.3 Peripheral tolerance
As a further safeguard to deal with autoreactive T cells which escape central 
tolerance, peripheral tolerance mechanisms also exist. There are a number of 
explanations for self reactive T cells being able to evade central tolerance. Despite 
the presence of the AIRE gene, not all peripheral antigens are expressed in the 
thymus, or they may be presented at too low a level, or on too few cells, to induce 
clonal deletion.
Peripheral tolerance may occur by a number of mechanisms. Self reactive T cells 
may be “ignorant” of their self antigen: the antigen may be expressed in anatomical 
sites that the T cell cannot access, or may be expressed at too low a level to activate 
the T cell (79;80). Alternatively, self reactive T cells may be deleted in the periphery 
(81) or rendered anergic. Anergic T cells are unresponsive: they do not produce IL-2 
when the TCR binds its cognate antigen and are unable to proliferate. Anergy can 
result from a TCR binding its cognate antigen in the absence of a second 
costimulatory signal, or in the presence of CTLA-4 binding to CD80 or CD86 (82;83).
Regulatory T cells
Regulatory T cells (Tregs) make up approximately 5-10% of CD4 T cells and are 
characterised by the expression of CD25 and the transcription factor FoxP3. They 
are a subset of T cells of thymic origin which actively suppress activation of the 
immune system via cell to cell contact, and prevent autoimmune disease resulting 
from pathological self-reactivity (84;85).
The critical role regulatory T cells play within the immune system is evidenced by the 
severe autoimmune syndrome that results in mice which lack CD4+CD25+ regulatory 
T cells (86). However, Tregs are also thought to play a role in tumour immunity by 
suppressing anti tumour responses. This concept is supported by the isolation of 
tumour specific CD4+ regulatory T cells from tumour infiltrating lymphocytes, as well 
as the observation that removal of CD4+/CD25+ regulatory cells resulted in the in 
vivo eradication of tumours in a murine model(87;88).
1.6 Antigen specific immunotherapy of cancer
1.6.1 Vaccination
This is a form of active immunity whereby antigen is administered in order to 
generate a protective or therapeutic immune response within the host. In tumour 
immunotherapy, the aim of vaccination is to expand a population of autologous
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tumour specific cytotoxic T cells (CTL) in vivo which can mediate tumour regression. 
Vaccination has seen widespread success in preventing the spread of infectious 
diseases, and is an attractive concept for tumour immunotherapy as vaccines are 
cheap, easy to administer on an out-patient basis and have relatively non-toxic side 
effects. Effective vaccines need to be immunogenic and stimulate T cell and antibody 
responses, but in the case of cancer vaccines also need to show a measurable 
clinical response.
Although cancer vaccines based on synthetic peptides, DNA, tumour cells, dendritic 
cells and several viruses have all been tested, response rates overall have generally 
been disappointing: a recent review by Rosenberg et al collated the data from trials 
amassing 440 patients (the majority of whom had melanoma) treated with a range of 
different cancer vaccines between 1995 and 2004. Objective clinical responses were 
measured according to the Response Evaluation Criteria in Solid Tumours (RECIST) 
criteria, or defined as at least a 50% reduction in the sum of the diameters of all 
lesions without any other lesion growing by more than 25% or any new lesions 
appearing. Using these combined criteria, they saw an overall response rate of only 
2.6% (89).
One reason for this may be because vaccination relies on the patients’ own immune 
system to mount a response, and patients may be immunocompromised due to 
previous chemotherapy, radiotherapy or metastatic disease. It could also be that high 
avidity CTL are either not present or not expanded as a result of central or peripheral 
tolerance mechanisms.
As with vaccination against infectious agents, it seems likely that vaccination against 
tumour antigens will prove most effective when used prophylactically, rather than 
when a tumour has already arisen. Prophylactic vaccination has been shown to 
protect against later tumour challenge in murine models (90-93), but active 
vaccination with TAAs once the animal has an established tumour has not seen the 
same success. Prophylactic vaccination for tumours caused by chronic viral infection 
is well established: hepatitis B vaccination has reduced the incidence of 
hepatocellular carcinoma and a license has recently been granted for a vaccine 
which targets epitopes of Human Papilloma Virus (HPV) and protects against 70% of 
cervical cancer (94;95). It is of note that there are no tolerance issues when targeting 
viral tumour antigens.
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1.6.2 Adoptive T cell transfer
In this method, the antigen specific effectors of immunity are directly administered, 
bypassing the obstacles in the host that might prevent the generation of an effective 
response in vivo. Large numbers of cells may be expanded in vitro, and can be 
selected to be of high avidity and tested for anti tumour activity before transfer into 
patients.
The adoptive transfer of antigen specific T cells was first used to good effect in the 
treatment of Epstein Barr virus (EBV) and cytomegalovirus (CMV) infection or 
reactivation occurring in immunosuppressed bone marrow transplant patients . EBV 
related post transplant lymphoproliferative disease (PTLD) is a significant cause of 
morbidity and mortality in transplant recipients. EBV-specific T-cell lines, prepared 
from peripheral blood collected from donors on the day of marrow harvest, have been 
used both prophylactically (in patients thought to be at risk of developing PTLD), and 
therapeutically with good clinical effect (96;97). Cytomegalovirus (CMV) infection or 
reactivation is another cause of morbidity and mortality post bone marrow transplant. 
Clinical protocols have been developed which isolate CMV-specific T cells from the 
transplant donor and adoptively transfer them to the patient after transplantation. This 
has proven effective in the prevention of reactivation and treatment of CMV infection 
that is unresponsive to antiviral therapy (98-100).
1.6.3 Autologous lymphocyte transfer
Researchers have looked at ways of directing patients’ own T cells against tumours. 
It has previously been shown that mice with established tumours expressing the 
melanoma-melanocyte differentiation antigen gp100 demonstrated long term tumour 
regression after receiving gp100 specific CD8 T cells, combined with vaccination and 
IL-2 (101). In melanoma patients it has been possible to isolate T cells specific for 
melanoma antigens (e.g. gp100 and MART-1) from extracted tumours: tumour 
infiltrating lymphocytes (TIL). These cells can be cultured ex vivo to expand their 
numbers and can then be tested for anti-tumour activity in vitro before adoptively 
transferring these cells back to patients.
In a study of 13 HLA A2 melanoma patients with progressive disease refractory to 
standard therapy, TIL which recognised melanoma antigens were isolated from 
patients and expanded ex vivo. T cells which were reactive against either an A2 
positive melanoma cell line or an autologous melanoma cell line in vitro were then 
selected for adoptive transfer. Patients underwent non-myeloablative chemotherapy
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conditioning before receiving on average 7.8 x10x1° cells and 9 doses of IL-2. 6 out 
of 13 patients showed objective clinical responses, with 4 further patients showing 
mixed responses. This study was extended to include a total of 35 patients, for whom 
the objective response rate (defined as >50% reduction in tumour size) was 51%, 
including four patients who showed a complete response. Analysis of 25 of these 
patients showed a statistically significant correlation between the persistence of 
antigen specific T cells and objective tumour regression (102).
The significant advantages of this method are the high response rate and the ability 
to test the T cells before returning them to the patient. However, there are a number 
of practical limitations with this type of adoptive therapy. It is not always possible to 
isolate TIL from all patients, nor all tumour types, and it is also a very labour intensive 
process requiring the expansion of a specific set of cells for each individual patient. 
Despite these limitations, the proof of principle remains: autologous cells which 
recognise TAAs can be adoptively transferred into melanoma patients, and these 
cells can expand and show anti-tumour activity in vivo.
1.7 Targeting WT1 for cancer immunotherapy
WT1 is a TAA which is currently being evaluated by several research groups as a 
target for the immunotherapy of leukaemia and solid tumours. WT1 encodes a 
transcription factor which can act as a transcriptional activator or repressor. The 
carboxyl terminus contains 4 zinc finger domains which mediate DNA binding, 
whereas the amino terminus consists of a transcriptional repression domain followed 
by a trans-activation domain (103; 104).
WT1 exists as a number of different splice variants and isoforms, the exact function 
of which have not all been elucidated. Alternative splicing of the WT1 transcript gives 
rise to four major splice variants which are conserved across mammalian species, 
each with different functional properties. One splice results in the insertion of the 
amino acids KTS between zinc fingers 3 and 4, which alters the DNA binding ability 
of WT1. Another splice results in the insertion of a 17 amino acid sequence encoded 
by exon 5. There are 24 different isoforms resulting from alternative splicing, different 
translational start sites, RNA editing or alternative promoters, and a truncated form of 
WT1 has been described in association with a number of leukaemias and solid 
tumours (105-109).
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Elevated expression of WT1 is a feature of many leukaemias and solid tumours, and 
high levels of WT1 expression are associated with a poor prognosis in breast cancer 
and leukaemia (110;111). Thus, a strategy which targets WT1 can be used against a 
wide variety of tumours and in a large number of patients. In addition, WT1 appears 
to be important in maintaining the malignant phenotype. When cell lines over­
expressing WT1 were treated with WT1 antisense oligomers, the growth of these 
cells was significantly inhibited in association with a reduction in WT1 protein levels. 
This indicated that WT1 is essential for the growth of malignant cells and performs an 
oncogenic rather than a tumour-suppressor gene function in these circumstances 
(112-114). Tumours often try to evade the immune system by downregulating 
expression of target antigens. However, if WT1 is required for maintenance of the 
malignant phenotype, then downregulation of WT1 in response to immunotherapy will 
adversely affect tumour survival.
Although expression of WT1 in the adult is largely limited to renal podocytes and 
haematopoetic stem cells, WT1 is required for fetal urogenital development, and 
expression of WT1 during fetal development is extensive. WT1 is also expressed at 
low levels in the thymus (115). This is likely to result in central tolerance towards 
WT1 and the deletion of CTL which recognise WT1 with high avidity, which is a 
potential problem for a WT1 based immunotherapy approach.
However, WT1 specific T cells can escape central tolerance. It has been 
demonstrated that vaccination with WT1 peptides in mice and in humans can 
generate WT1 CTL responses, indicating that tolerance to WT1 is incomplete 
(93;116;117). Whether vaccine induced WT1 specific T cells are of sufficient avidity 
to kill WT1 expressing tumour cells in vivo is not clear at present.
1.8 TCR gene transfer
In recent years a new strategy has evolved to facilitate the adoptive transfer of 
autologous T cells which are specific for TAAs. This technique enables the 
production of autologous, antigen specific T cells. It overcomes the problem of 
central tolerance to TAA and the need for the host to mount an immune response 
against tumour antigens. TCR gene transfer also avoids the requirement for 
individually tailored therapy which is a drawback seen with the transfer of autologous 
TIL. Further advantages of this strategy are that the introduced specificity can be 
targeted against poorly immunogenic targets and the introduced genes can be 
selected to code for a high affinity TCR.
29
1.8.1 Structure of the TCR
The a(3 TCR is a heterodimer linked by a disulphide bond in the hinge region, which 
is located above the transmembrane region of each chain. The variable region of the 
TCR determines its antigen binding specificity. TCR diversity is generated by TCR 
gene rearrangement in the thymus, and it is in complementarity determining region 
(CDR) 3 that diversity is concentrated. Each TCR variable region contains three 
CDRs which interact with the peptide:MHC complex. CDRs 1 and 2 are mainly in 
contact with the MHC molecule, whereas the CDR3 region interacts extensively with 
peptide residues. Each T cell expresses a single TCR specificity. (118;119).
1.8.2 TCR:CD3 complex
The CD3 complex is required in order for a TCR to be expressed at the cell surface, 
and to transduce signals intracellularly upon antigen binding by the TCR. The CD3 
complex is composed of 4 invariant chains: gamma, delta, epsilon and zeta. One 
epsilon and one delta chain form a heterodimer, as do one gamma and one epsilon 
chain. Whereas these heterodimers are largely extracellular and are required for 
TCR surface expression, two zeta chains form a homodimer which is largely 
intracellular (Figure 1.1). The CD3 gamma, delta and epsilon proteins are encoded 
on chromosome 11, separately from the zeta chain on chromosome 1. Expression of 
the CD3 genes is restricted to cells of T lymphocyte lineage. The CD3 complex is 
expressed early in thymocyte development and precedes TCR gene rearrangement 
and expression: CD3 epsilon, delta and gamma mRNA can be isolated from the 
earliest thymocytes (120;121). The TCR/CD3 complex is assembled in the ER and 
the zeta chains are the last component to be integrated before the complex is 
transport to the cell surface. (122-124).
1.8.3 TCR signal transduction
Binding of a TCR to its cognate peptide:MHC complex results in signal transduction 
which ultimately leads to changes in gene transcription, giving rise to a range of T 
cell effector functions. Clustering of TCRs upon antigen binding leads to 
rearrangement of the cytoskeleton and the formation of a supramolecular adhesion 
complex (SMAC), in which the TCRs co-localise with the necessary coreceptors 
(such as CD4 and CD8), other signalling molecules and adhesion molecules. 
Formation of a SMAC on a T cell then causes the TCR ligands on an APC or target 
cell to be concentrated in proximity with the SMAC. The site of contact between the T
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CD3 epsilon
ITAM
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Figure 1.1: the TCR:CD3 complex. The apTCR associates with a complex of 
invariant CD3 chains, which are necessary for both TCR expression on the cell 
surface as well as signal transduction upon antigen recognition. Two CD3e chains 
form heterodimers with a CD3y and a CD35 chain, respectively, and two CD3 £ 
chains form a homodimer. The intracellular regions of the CD3 chains contain 
immunoreceptor tyrosine-based activation molecules (ITAMs). Antigen binding to the 
TCR results in phosphorylation of the ITAMS, initiating signal transduction pathways 
which ultimately lead to changes in gene transcription and a range of T cell effector 
functions.
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cell and its target is called the immunological synapse: a highly organised interface 
which provides an optimal environment to facilitate T cell activation and signal 
transduction. (125; 126).
The a and |3 TCR chains have very short intra-cytoplasmic domains which are 
incapable of signal transduction. In contrast, all the CD3 chains contain 
immunoreceptor tyrosine based activation motifs (ITAMS) for signal transduction. 
Each of the two CD3 epsilon chains, the CD3 gamma and CD3 delta chains have 
one ITAM, and each of the two zeta chains have 3 ITAMS. Therefore the TCR/CD3 
complex contains 10 ITAMS in total.
Proximal events in TCR signalling are dependent on the Src family kinases Lck and 
Fyn, which contain a tyrosine residue at both the amino and the carboxy terminus. 
Phosphorylation of the tyrosine at the amino terminus stimulates kinase activity, 
whereas phosphorylation at the carboxy terminus inactivates the kinase by causing a 
conformational change that blocks the active site. C-terminal Srk Kinase (Csk), which 
phosphorylates the inhibitory tyrosine, is constitutive in resting cells, so the Src 
kinases are usually inactive at rest. The tyrosine phosphatase activity of CD45 
removes the inhibitory phosphate, which allows Lck and Fyn to become activated. 
Once activated, Lck and Fyn phosphorylate tyrosine residues on CD3 chain ITAMs, 
which allows ZAP-70 to bind. Lck then phosphorylates and activates the ITAM-bound 
ZAP-70. Activated ZAP-70 phosphorylates the adaptor proteins SLP-76 and linker of 
activated T cells (LAT), which are important in subsequent intracellular signal 
transduction (127-129).
Phosphorylation of the zeta chain ITAMs is an important early event in TCR signal 
transduction. The importance of the zeta chain is illustrated when zeta chain 
expression is downregulated in association with a number of chronic infections and 
malignancies. In these circumstances, T cells with reduced zeta expression are still 
able to express TCR/CD3 complexes on the cell surface, but the T cells are 
functionally impaired as a result of impaired signal transduction (130).
1.8.4 Retrovirally mediated TCR gene transfer
TCR gene transfer makes it possible to target T cells to antigens of interest, including 
tumour antigens. The allo-restricted strategy can be used to isolate high avidity CTL 
which are specific for the target antigen (131-133). The TCR a and (3 chains can then 
be isolated from these CTL and cloned into vectors, which are then used to 
transduce patients’ T cells. The recipient T cell expresses the introduced TCR on its
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surface, hence its specificity has been redirected, as it will now recognise the tumour 
antigen of interest (Figure 1.2).
The first demonstration of TCR gene transfer being used to successfully transfer 
TCR into target (hybridoma) cells occurred in 1986, at which point it was also shown 
that the expressed TCR retained the MHC-restricted antigen specificity of the T cells 
from which the genes were originally cloned (134). Since then, this technology has 
been used to redirect the specificity of T cells against a range of viral, tumour and 
other targets. Clay et al first demonstrated that TCR gene transfer could be used to 
generate human T cells which released interferon gamma in response to tumour cells 
(135). Furthermore, by transferring allo-restricted TCRs into autologous T cells, it is 
possible to circumvent tolerance and generate high avidity autologous cells which 
recognise TAA (136).
Since commencing my PhD, TCR gene transfer has seen clinical success in a recent 
Phase I trial in melanoma patients. Retroviral gene transfer was used to transduce 
peripheral blood lymphocytes, taken from patients with melanoma, with the genes 
encoding the a and (3 chains of the anti MART-1 TCR. The genes for this TCR, which 
recognises a melanoma associated antigen, were cloned from a TIL clone obtained 
from a melanoma patient who showed a good clinical response to adoptive T cell 
therapy (137). This study, while small, demonstrated proof of principle: retroviral TCR 
gene transfer can be used to confer anti tumour specificity upon a large number of T 
cells, and that these T cells can engraft in cancer patients and persist at high levels 
long term. However, only 2/17 patients responded clinically to treatment with 
genetically modified T cells (12%), suggesting that further improvements are needed 
to enhance the therapeutic efficacy of TCR modified cells.
1.8.5 Augmenting the TCR transfer strategy
A number of strategies are being investigated in order to augment the TCR gene 
transfer concept. The majority of these involve manipulation of the TCR itself, such 
as making alterations to the TCR constant region in order to reduce mispairing and 
increase expression.
1.8.6 Competition for CD3
One of the aims of this work is to investigate whether the sensitivity of a TCR can be 
increased without altering the TCR itself. The availability of the CD3 complex may be
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Figure 1.2: TCR gene transfer
(i) A T cell bearing the appropriate TCR is identified, (ii) the a and (3 TCR chain genes 
are isolated and cloned into a retroviral vector, (iii) the vector is used to transfect a 
packaging cell line which produces viral particles containing the genes of interest: 
(iv). (v) Target T cells are transduced with the recombinant viral particles; (vi) when 
the genes integrate into the host DNA the target cells express the desired TCR
34
a rate limiting step for the expression of TCRs, especially following TCR gene 
transfer, when there are both endogenous and introduced TCRs competing for 
surface expression. I have therefore chosen to investigate whether co-transduction of 
CD3 can augment the expression and function of a TCR introduced by retroviral 
gene transfer.
1.9 Aims of the project
This project is an extension of ongoing work in the laboratory focussing on WT1- 
specific immunotherapy. The main focus of the laboratory to date has been on 
leukaemia; there is presently limited information regarding WT1 as a target for the 
immunotherapy of solid cancers. The two immunotherapeutic strategies being 
investigated by the laboratory are vaccination, which aims to stimulate an autologous 
T cell response to WT1, and TCR gene transfer, in which immunity to WT1 is 
acquired by retroviral gene transfer.
The first aim of this project is to evaluate WT1 as a target for the immunotherapy of 
prostate cancer, and explore autologous T cell responses to WT1 in patients with 
prostate cancer.
The second aim of this project is to enhance the efficacy of TCR gene transfer. Firstly 
I will assess whether CD3 is a rate limiting step for TCR expression in T cells, and 
secondly I will investigate whether the expression and sensitivity of a TCR introduced 
by retroviral gene transfer can be increased by the co-transduction of CD3.
1.9.1 Hypotheses
In this thesis I will test the following working hypotheses:
1. WT1 is aberrantly expressed in prostate cancer
2. WT1 specific CTL are detectable in patients with prostate cancer
3. Impaired T cell function in prostate cancer patients can be reversed with IL-15
4. Co-transfer of TCR and CD3 can enhance the TCR expression of gene 
modified cells
5. Co-transfer of TCR and CD3 can enhance the antigen specific function and 
sensitivity of gene modified cells
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Chapter 2: Materials and Methods
2.1 In vitro cell culture
2.1.1 Tumour cell lines and culture condition
Ecotropic Phoenix cells (Phoenix-eco) were used as the packaging line for 
production of retroviral particles. They were grown in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (Cambrex) supplemented with membrane filtered 10% heat- 
inactivated foetal calf serum (HI FCS) (Biowest, Nuaille, France), 1% 
penicillin/streptomycin (Invitrogen) and 2mM L-glutamine (Sigma-Aldrich)(Eco 
medium).
All other tumour cell lines were cultured in Normal Growth Medium (NGM): Roswell 
Park Memorial Institute 1640 (RPMI) medium (Invitrogen, Paisley, UK), 
supplemented with 10% HI FCS, 100U/ml penicillin, 100pg/ml streptomycin and 2mM 
L-glutamine. All cell lines were grown in suspension other than Phoenix-eco cells, 
which is an adherent cell line. All cells were cultured in a 37°C humidified incubator 
with 5% C02.
The T2 cell line is a Transporter Associated with Antigen Processing (TAP) deficient 
cell line whose HLA-A2 Class 1 molecules are inefficiently loaded with peptide. Class 
I molecules can be stabilised at the cell surface by loading them with exogenous 
peptide (138). RMA-S is the murine equivalent: a TAP deficient derivative of the RMA 
cell line which can efficiently present exogenously loaded peptide and was derived 
from a Rauscher virus-induced C57/B6N T cell lymphoma (139; 140). On the day 
prior to loading RMA-S cells with peptide they were placed in a waterbath at 26°C 
overnight, in a sealed tissue culture flask, in gassed NGM at a density of 5- 
10x105/ml. This temperature induction increases the surface expression of MHC 
Class I molecules so that they can be more efficiently loaded with exogenous peptide 
(141)
58a‘p‘ cells were grown in NGM. This is a TCR negative variant of the DO-11.10 T cell 
hybridoma cell line (142).
2.2 Patient clinical samples
2.2.1 Ethics committee approval
Ethics committee approval for this research was granted by the Royal Free Hospital 
and Medical School Local Research Ethics Committee (REC reference number:
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05/Q0501/161). All clinical samples were obtained after having first gained written 
informed consent from the patient.
2.2.2 Preparation of mononuclear cells from whole blood
PBMC were separated from blood by density gradient separation. The blood sample 
was mixed 1:1 with warm RPMI 1640, then 30ml aliquots were gently layered onto 
15mls of Lymphoprep (Fresinius Kabi, Norway) in a 50ml Falcon tube. After 
centrifugation at 2000rpm for 30 mins (without centrifuge braking), an interface 
containing PBMC was visible between the plasma above and lymphoprep/red cell 
pellet below. The interface was pipetted off and re-suspended in RPMI. A further 
three washing steps were performed at 1600, 1300 and 1100rpm (with the brake on). 
Cells to be stored were counted, resuspended in membrane filtered freezing medium 
(90% FCS, 10% Dimethyl Sulfoxide (DMSO), [Sigma, UK]) and aliquoted into 
cryovials. After 30 minutes on ice, cryovials were stored in -80°C freezer for 24 hours 
before transfer into liquid nitrogen.
2.3 WT1 Immunohistochemistry
Prostate cancer tissue array PR 951 was obtained from US Biomax Inc. (Ijamsville, 
US). The immunohistochemistry was carried out by the Department of 
Histopathology, Hammersmith Hospital who kindly provided the following protocol:
a) slides were stained on a Bond max machine, which automates the de-waxing 
and antigen retrieval steps as well as the staining.
b) Antigen retrieval in the ER2 solution (pH 9.0) for 30 min
c) The detection system is from Vision Biosystems (BondPolymer Define)
d) Primary antibody (Novocastra) incubation at 1/400 for 20 mins
e) Post primary antibody incubation for 15 min
f) Polymer incubation for 15 min
g) DAB for 10 min, enhance for 5 min
For each immunohistochemical reaction, a negative control without primary antibody 
was included. All samples were analysed by myself and Dr Fabrizio Corsi from the 
Department of Histopathology, Hammersmith Hospital. Both researchers were 
blinded to the clinical characteristics of the samples being analysed.
2.4 Flow cytometry
Unless otherwise stated, all flow cytometric agents were purchased from BD 
Biosciences, Oxford, UK.
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2.4.1 Staining for cell surface molecules
Direct immunofluorescence was used to stain for cell surface molecules as follows: 
approximately 5 x105 cells were used per sample. Cells were washed in cold staining 
buffer (PBS with 1% HI FCS) and resuspended in 50pl staining buffer containing the 
appropriate dilution of the relevant monoclonal antibody. Samples were incubated at 
4°c for 25 minutes in the dark, washed twice with staining buffer and resuspended in 
300pl staining buffer prior to analysis. Propidium iodide (PI; Sigma Adrich) was 
added to give a final concentration of 0.1pg/ml to distinguish dead cells, which take 
up PI. PI gives a signal in both the FL2 and FL3 channels, allowing PI positive cells 
to be excluded from further analysis. Flow cytometry antibodies used were: FITC 
labelled anti-human CD3s, APC labelled anti-murine TCR (3 chain constant region, 
anti-murine Va2 and anti-human CD8, labelled anti-murine CD3e, anti-murine 
vp11, anti-human CD8-PE and anti-human V|32.1 (Immunotech)
2.4.2 Tetramers and peptides
2.4.2.1 Synthetic Peptides
All peptides were obtained from Proimmune, Oxford, UK. The synthetic peptide 
pWT126 corresponds to amino acids 126-134 (RMFPNAPYL) of the Wilms’ tumour 
protein (WT1). The synthetic peptide pMelan-A corresponds to amino acids 26-35 
(ELAGIGILTV) of the Melan-A protein, but with a leucine substituted for the alanine at 
position 27. This amino acid substitution results in an increased binding of the 
peptide to the HLA-A*0201 molecule and a corresponding increase in antigenicity of 
the peptide(143;144), but tetramers containing the modified pMelan-A also bind T 
cells which recognise the unmodified peptide (145).
The influenza virus A NP-derived peptide, pNP366 (ASNENMDAM), and the control 
peptides pMDM100 and pSV9 all bind to the H2-Kb molecule. The pMDM100 
(YAMIYRNL) is derived from the murine double minute (MDM) 2 protein, and pSV9 
(FAPGNYPAL) is derived from the Sendai virus.
Peptides were re-constituted from powder to a 20mM stock solution in distilled water 
(45%), DMSO (50%) and dithiothretol (DTT) (5%). 2mM aliquots were then prepared 
(to minimise repeated freeze-thawing of stock) and stored at -20°C
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2.4.2.2 Tetramer staining
Phycoerythrin (PE)-labelled tetramers consisting of a specific peptide bound to H2-Kb 
or HLA-A*0201 Class I molecules were used to detect antigen specific CD8 T cells. 
The influenza tetramer was obtained from Proimmune, Oxford, UK. All other 
tetramers were obtained from Beckman Coulter, France, and contained an amino 
acid substitution (alanine replaces valine at position 245) in the a3 chain of the MHC 
Class I molecule, resulting in a reduced interaction with CD8 molecules. These 
mutated tetramers have been showri to display reduced non-specific binding 
resulting from interaction with CD8 molecules, while not reducing specific binding to 
TCR molecules (146;147).
Tetramer staining on PBMC was performed on between 1-5 x106 cells. (When low 
frequency events were expected, a greater number of cells were stained and a 
greater frequency of events recorded.) Cells were washed in FACS buffer and 
resuspended in 50pl of a 1 in 50 dilution of tetramer for 20 minutes at room 
temperature, in the dark. Cells were washed once in FACS buffer before being 
stained with directly conjugated antibodies to CD3 and CD8. Samples were 
incubated at 4°C for 20 minutes in the dark, washed twice in FACS buffer and 
resuspended in 400pl FACS buffer for analysis. PI was added to distinguish dead 
from viable cells. Analysis was performed on gated viable, CD8 positive T cells.
2.5 T cell culture
Standard T cell culture medium consisted of RPMI 1640 containing 10% HI FCS, 1% 
penicillin/streptomycin and 1% L-glutamine.
2.5.1 T cell culture day 0
Mononuclear cells or murine splenocytes were grown in vitro and stimulated every 7- 
10 days in a peptide specific manner. Cells were suspended in NGM at a density of 
3x106 PBMC in a 24 well plate containing 2ml of media and peptide at a final 
concentration of 10 pM. The cytokines IL-2 (Roche, Lewes, UK) and IL-7 (R&D 
Systems, Abingdon, UK) were added to the medium on day 0 at a concentration of 
20units/ml and 2.5ng/ml, respectively. Alternatively, IL15 was added to the medium 
on day 0 at a concentration of 50 units/ml (R&D Systems, Minneapolis). The cells 
were incubated at 37°C, 5% C02 for 7-10 days.
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2.5.2 Restimulation of T cell cultures
Restimulation was carried out every 7-10 days after tetramer staining had been 
performed. Restimulation involved plating the cells at a density of 5 x 105 per 2 ml of 
T cell medium containing IL2 at a concentration of 20 units/ml, or IL15 at a 
concentration of 50 units/ml. Cultures were stimulated using irradiated (80 Gy) T2 or 
RMA-S cells (for human or murine T cells, respectively,) loaded with 100 pM of the 
relevant peptide (2x105 T2 or RMAS cells per well). Irradiated (30 Gy) PBMC from 
healthy HLA-A2 positive donors obtained from the National Blood Service (Colindale, 
UK), or C57BL/6 splenocytes, were used as feeder cells (2x106 cells per well)
2.6 Magnetic bead sorting
2.6.1 Depletion of endogenous V(311 positive splenocytes
When Vp11 depleted splenocytes were required for transduction, splenocytes were 
separated prior to activation, on day 2 of the transduction protocol, using MACS PE 
beads according to the manufacturer’s protocol (Miltenyi Biotec, Bisley, Surrey, UK). 
Briefly, cells were surface stained with V(311-PE antibody for 30 minutes on ice, 
before being washed in 1ml MACS buffer (PBS pH7.2 containing 0.5% BSA and 
2mM EDTA) per 1 x107 cells and centrifuged for 10 minutes at 300xg. Cells were 
then incubated with 40pl PE microbeads and 60pl MACS buffer per 1x107 cells, on 
ice, for 20 minutes. Cells were then washed with 1ml MACS buffer per 1 x107 cells 
and centrifuged for 10 minutes at 300xg.The pellet was then resuspended in 500pl 
MACS buffer per 1 x108 cells. Magnetic separation was performed using an MS 
column placed in the magnetic field of a MiniMACS separator. The column was 
prepared for use by applying 500pl MACS buffer and allowing it to run through. The 
cell suspension was then applied to the column, which was subsequently washed 
three times with 500pl MACS buffer, collecting the unlabelled, V(311 depleted cell 
fraction. Cells were then counted and activated with ConA and IL-7 as previously 
described.
2.7 Generation of TCR transduced T cells
2.7.1 Retroviral vectors
The retroviral vectors pMX-TCRa-IRES-TCRp (F5 TCR) and pCL-Eco were a kind 
gift from T. Schumacher (Nederlands Kanker Institute, Amsterdam) (148). pCL-Eco is 
a retroviral vector encoding an ecotropic envelope, which is used to enhance 
retroviral transduction of murine cells. The pMX vector is based on Moloney murine 
leukaemia virus. The F5 TCR recognizes the influenza virus A NP (NP366-379) 
peptide in the context of murine Db MHC class I. The retroviral vector pMSCV-CD35-
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CD3y-CD3£-CD3£-IRES-GFP (CD36-GFP) is a murine stem cell virus based vector 
and was a kind gift from D.Vignali (University of Tennessee Medical Center, USA) 
(149).The retroviral vector pMP71-TCRa-2A-TCR(3 (WT1 TCR) is a 
myeloproliferative sarcoma virus based vector. The WT1 TCR recognises the WT126 
peptide in the context of HLA-A*0201. The constant regions of the a and (3 TCR 
chains have been replaced with murine constant regions, which also contain 
additional cysteine residues and have been codon optimized, as described previously 
(150; 151). The retroviral vector pMP71-CD3£-CD3£-CD3y-CD35-IRES-GFP (CD3£- 
GFP), in which the order of the CD3 chains is reversed, was constructed by Geneart 
(Regensburg, Germany). The 2A sequences linking the CD3 chains are unchanged 
from the CD35-GFP vector, but the CD3 genes have been codon optimised and 
cloned into the pMP71 vector. In the retroviral vector pMP71-rWT1-IRES-GFP (GFP 
control), the WT1 gene has been inserted into the cloning site in reverse orientation 
such that only the GFP is translated from this vector.
2.7.2 Transfection and generation of retroviral particles
1.8x106 Phoenix-eco cells were seeded in a 60cm2 (96x21 mm) sterile tissue culture 
treated Petri dish (TTP, Trasadingen, Switzerland) in 10ml of eco medium 24 hours 
prior to transfection and incubated in a humidified atmosphere at 37°C with 5% C02 
(day 0). Transfection took place on day 1. A transfection mixture was prepared 
containing the following: 7.5pl (7.5pg) pCL-eco, 18pl 2M Calcium Chloride 
(CaCI2)(lnvitrogen), either 10 pi (10pg) of TCR expressing vector or 5 pi (5pg) of 
CD3 expressing vector or 5 pi (5pg) of GFP expressing vector, plus dH20 to make a 
total volume of 150 pi. Control experiments were carried out in all experiments, with 
the vector being replaced with an equivalent volume of dH20. The transfection 
mixture was then added drop-wise to 150pl of 2xHBS (Invitrogen) while air was being 
bubbled through it to form a fine precipitate. The transfection mixture was then left for 
30 minutes at room temperature while the medium was removed from the Phoenix 
eco cells to be replaced with 5mls of fresh medium, taking care not to disrupt the 
cells. After the 30 minute incubation the DNA transfection mix was added drop wise 
to the Phoenix cells, which were then incubated in a humidified atmosphere at 37°C 
with 5% C02. 18 hours post transfection (day 2), the medium was removed, the 
Phoenix cells carefully washed once with warm PBS and 5ml of NGM was placed on 
the Phoenix cells which were returned to the incubator for a further 24 hours.
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2.7.3 Retroviral transduction
Freshly isolated C57BL/6 (H2b) splenocytes were activated for 2 days prior to 
transduction with 2pg/ml concavalin A (conA) (Sigma-Aldrich) and 1ng/ml 
recombinant IL-7 (R&D Systems) (day 1). On day 3, 6-well non-tissue culture treated 
plates (Greiner Bio-One, Stonehouse, Gloucestershire, UK) were coated with 2.5ml 
30 pg/ml Retronectin (Takara-Bio Inc, Otsu, Japan) per well and incubated at room 
temperature for 2-4 hours. Retronectin is a human fibronectin peptide which 
increases transduction efficiency by co-localising viral particles and target cells on 
the retronectin molecules (152). Following this incubation the Retronectin was 
removed and the plates were blocked with 3ml/well 2% BSA (Sigma-Aldrich) diluted 
in PBS for 30 minutes at room temperature. This was then removed and the plates 
washed twice with PBS. 2.5x106 58a'p' cells or activated splenocytes were added to 
each well. Viral supernatant was harvested and centrifuged before 2ml of 
supernatant was added to the cells along with NGM to make a total volume of 5ml 
per well. For example: cells transduced with the CD3 vector would receive 2ml 
supernatant and 3ml NGM, whereas cells transduced with the CD3 vector and the F5 
TCR vector would receive 2ml of CD3 supernatant, 2ml of F5 supernatant and 1ml of 
NGM. In addition, splenocyte cultures received 100U/ml recombinant human IL-2 
(Chiron). On days 4 and 6, cells were harvested and resuspended in 6ml fresh NGM 
(containing 100U/ml for splenocyte cultures) in a tissue culture treated 6 well plate. 
Transduction efficiency was assessed by flow cytometry on day 6.
2.7.4 Assessment of transduction efficiency by flow cytometry
Transduction efficiency was determined by staining with 5-10x105 cells with 
tetramers and surface antibodies in FACS buffer as described above. Samples were 
then resuspended in FACS buffer and analysed using an LSRII flow cytometer and 
FACSDiva software
2.8 In vitro functional assays
2.8.1 IL-2 ELISA
On day 5 after transduction 5x104 peptide loaded RMA-S or T2 cells were incubated 
with 5x104 transduced splenocytes or 1x105 transduced 58a'p'cells, in 200ml NGM, in 
triplicate. After 24h, the supernatant was harvested and tested in an IL-2 ELISA 
assay using a Beckon Dickinson OptEIA™ mouse ELISA set according to the 
manufacturer’s instructions (BD Biosciences). Briefly, 96-well ELISA plates (Nunc) 
were coated with 100pl per well with anti-mouse IL-2 capture antibody and incubated 
overnight at 4°C. Plates were washed three times and blocked for 1 hour at RT with
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200|jl assay diluent. Plates were then washed three times. Recombinant mouse IL-2 
dilutions were prepared in assay diluent as standards. Standards were prepared in 
triplicate from 200pg/ml, in double dilutions to 3.1pg/ml. Supernatant was harvested 
from stimulation plates after 24 hours. 100pl standard/supernant was added to each 
well and incubated at RT for 2 hours. Plates were washed 5 times and 100pl of 
working detector (biotinylated anti-mouse IL-2 and 1:500 avidin-horseradish 
peroxidise conjugate) added to each well. Plates were incubated at RT for 1 hour, 
then washed 7 times. 100pl of substrate solution was added to each well and 
incubated for 30 minutes in the dark, after which 50pl stop solution was added. The 
absorbance at OD450 was read using an ELISA plate reader (Titertek). Data are 
presented as the mean IL-2 concentration (pg/ml) +/- standard deviation of triplicate 
values.
2.8.2 IFN-y ELISA
IFN-y was measured in the culture supernatant of stimulated transduced 58a'p_ cells 
or T cells using a Becton Dickinson OptEIA™ mouse IFN-y ELISA kit (BD 
Biosciences) according to the manufacturer's protocol (as described above). Data 
are presented as the mean IFN-y concentration (pg/ml) +/- standard deviation of 
triplicate values.
2.8.3 Intracellular cytokine staining
Intracellular IFNy detection was performed using a BD Cytofix/Cytoperm™ 
Fixation/Permeabilisation Kit according to the manufacturer’s instructions. 1 x 106 
bulk transduced T cells stimulated with 5 x 105 T2 cells loaded with 10 pmol/L of 
either pWT126 or pMelan-A peptide. After 2 hours, Brefeldin A (Sigma) was added at 
a concentration of 10 M9/mL to block cytokine secretion. After another 12 hours, cells 
were stained with anti-murine CD8 APC and incubated at 4°C for 20 minutes. 
Following this, cells were resuspended in Fixation/Permeabilization solution for 20 
min at 4°C. After another two washes, cells were stained with IFNy-PE for 30 min at 
4°C in the dark. After a further 2 washes, samples were resuspended in 300 pL of 
PBS/1 % FCS prior to flow cytometric analysis.
2.8.4 IFN-y ELISPOT
This assay was performed performed using an IFNy ELISPOT kit (BD Biosciences) 
according to the manufacturer's instructions. Autologous PBMC (2x105/well) were 
added together with the indicated number of responder T cells (2x105/well) and 
peptide (5pg/ml) in 200pl NGM and incubated for 20 h at 37°C, in triplicate. Cells
43
were then discarded, plates were washed and developed with a second antibody to 
human IFNy (biotinylated) and streptavidin-alkaline phosphatase according to the 
manufacturer’s instructions. Responder cells and stimulators loaded with an 
irrelevant peptide, and responder cells without stimulator cells were used as negative 
controls. 200 ng/ml of staphylococcal enterotoxin B (SEB) was used as a positive 
control on 5x104 cells. Results are expressed as the mean number of spot forming 
units (SFU) per 106 cells from triplicate wells. Only cell samples with > 80% viability 
were analyzed, and only assays with <50 SFU/106 cells for the negative control and 
>500 SFU/106 cells after SEB stimulation were considered valid.
2.9 Annexin V staining
Annexin V staining was performed according to the manufacturer’s instructions (BD 
Biosciences). Cells were washed twice in cold PBS and resuspended in 1x binding 
buffer at a concentration of 1x106 cells/ml. 100pl of the solution was transferred to a 
5ml culture tube before adding 5pl of Annexin V-APC and 5pl of PI. The cells were 
gently vortexed and incubated for 15 min at 25°C in the dark. 400pl of binding buffer 
was then added and cells were analysed by flow cytometry within 1 hour.
2.10 Animals
Normal C57BL/6 (H2b) female mice were used as tissue donors. All animals were 
housed in a specific pathogen-free environment in accordance with institutional 
guidelines for animal care. C56BL/6 mice were obtained from Harlan, Oxon, UK.
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Chapter 3: Evaluating WT1 as a target for the immunotherapy of prostate 
cancer
3.1 Introduction
Prostate cancer is the commonest cancer in men in this country, with over 35,000 
new diagnoses each year, and the incidence worldwide is increasing steadily (153). 
The three most common treatment modalities, surgery, radiotherapy and androgen 
ablation, are all associated with significant side effects and reduced quality of life 
(154). It is therefore desirable to develop new immunotherapy options with the 
potential to selectively eliminate prostate cancer cells. Cytotoxic T cells (CTL) are 
important effectors of anti-tumour immune responses (155). The vast majority of 
CTL-recognised targets described to date are tumour-associated antigens such as 
the Wilms’ tumour antigen (WT1), which is currently being evaluated for the 
immunotherapy of a number of leukaemias and solid tumours. However, there is 
currently limited information regarding the expression and immunogenicity of WT1 in 
prostate cancer.
Immunological tolerance to tumour associated antigens such as WT1 remains a 
potential barrier to successful T cell immunotherapy. T cell unresponsiveness in the 
presence of tumours has been described in melanoma patients and in murine tumour 
models (12;156;157). Although interleukin 2 (IL2) was shown to reverse 
unresponsivenessis in classical T cell anergy, recent experiments in transgenic mice 
revealed that T cell tolerance was readily reversed by interleukin 15 (IL15), but not 
IL2 (158;159).
The aim of this chapter is to evaluate WT1 as a target for the immunotherapy of 
prostate cancer. I assessed WT1 expression in prostate cancer samples and 
evaluated whether there are measurable WT1 CTL in prostate cancer patients. 
Furthermore, I investigated whether these CTL could be expanded in vitro by peptide 
specific stimulation in the presence of different cytokines, and whether they could 
produce IFNy in response to antigen specific stimulation. This information would 
inform the design of immunotherapeutic strategies for prostate cancer patients.
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3.2 Results
3.2.1 WT1 expression in prostate cancer and normal controls
I assessed WT1 protein expression by WT1 immunohistochemistry. Prostate tissue 
microarray PR 951 was obtained from US biomax; patient characteristics can be 
found in Table 3.1. Immunohistochemistry was performed on fixed prostate cancer 
tissue using an lgG1 murine monoclonal antibody directed against amino acids 1-181 
of the N-terminal of the human WT1 protein. The conditions used to monitor WT1 
protein expression were those currently used in the diagnostic service laboratory in 
the Department of Cytology at the Hammersmith Hospital, London, where WT1 
expression is routinely monitored in patient samples. This assay was previously 
validated using kidney and ovarian carcinoma tissue as a positive control for WT 1 
protein expression, and skeletal muscle as a negative control. As a further negative 
control for non-specific binding by the secondary antibody, the primary antibody was 
replaced with assay diluent. The tissue arrays were graded by myself and Dr Fabrizio 
Corsi of the Department of Cytology, Hammersmith Hospital; both researchers were 
blinded to the patient characteristics.
Tissue array PR 951 contained duplicated cores of 36 prostate adenocarcinomas 
and 8 normal prostate samples. Reproducibility between the duplicates was high: 
there was discordance for only 1 duplicate sample, where one core showed 
cytoplasmic staining only, and one showed cytoplasmic as well as nuclear staining. 
(This sample was counted as showing nuclear as well as cytoplasmic staining in the 
final analysis.) Of the normal prostate samples, 100% displayed cytoplasmic staining 
only for WT1, with 0% nuclear staining (Figure 3.1, a). Of the adenocarcinoma 
samples, 56% showed cytoplasmic staining only, 39% stained in the cytoplasm as 
well as the nucleus (Figure 3.1, b) and 5% did not stain at all with the WT1 antibody. 
Where nuclear staining was present, it was heterogenous and the proportion of 
nuclei which were WT1 positive ranged from 40-60%. The difference in nuclear WT1 
staining between normal and adenocarcinoma samples was statistically significant to 
p<0.036 using Fisher’s Exact test. The degree of differentiation of the tumours seen 
histologically (Gleason grade) was not significantly associated with nuclear WT1 
staining. 14 out of 29 T3/T4 cancers (which extend through the prostate capsule) 
showed nuclear WT1 expression, whilst all seven T2 cancers (enclosed within the 
capsure) in this series were negative for nuclear WT1 expression, although this was 
not a statistically significant difference.
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Table 3.1 Characteristics of 36 cases of localised prostate cancer with 8 
matched normal prostate tissue samples, from tissue array PR951, on which 
WT1 immunohistochemistry was performed.
The Gleason score refers to the degree of differentiation of the tumours seen 
histologically, with 5 representing poorly differentiated tumours. Each sample 
receives two scores from 1-5 (e.g.: 3+4). Staining is graded from zero to +++.
ID Age Diagnosis TNM Gleason Nuclear Cytoplasmic
1 44 Malignant
adenocarcinoma
T3N0M0 7 + +
1 44 Normal prostate 
matched tissue
+
2 63 Malignant
adenocarcinoma
T4N0M0 10 + +
2 63 Normal prostate 
matched tissue
+
3 70 Malignant
adenocarcinoma
T2NOMO 7 +
3 70 Normal prostate 
matched tissue
+
4 70 Malignant
adenocarcinoma
T3N0M0 7 + +
4 70 Normal prostate 
matched tissue
+
5 69 Malignant
adenocarcinoma
T3N0M0 7 +
5 69 Normal prostate 
matched tissue
+
6 65 Malignant
adenocarcinoma
T3N0M0 9 +
6 65 Normal prostate 
matched tissue
+
7 62 Malignant
adenocarcinoma
T2N0M0 7 +
7 62 Normal prostate - - - +
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matched tissue
8 69 Malignant
adenocarcinoma
T2N0M0 7 +
8 69 Normal prostate 
matched tissue
+
9 63 Malignant
adenocarcinoma
T3N0M0 8 +
10 53 Malignant
adenocarcinoma
T4N0M0 9 + +
11 63 Malignant
adenocarcinoma
T4N0M0 9 + +
12 62 Malignant
adenocarcinoma
T4N0M0 9 +
13 75 Malignant
adenocarcinoma
T3N0M0 9 + +
14 70 Malignant
adenocarcinoma
T3N0M0 8 +
15 72 Malignant
adenocarcinoma
T4N0M0 8 +
16 57 Malignant
adenocarcinoma
T4N0M0 7 + +
17 68 Malignant
adenocarcinoma
T3N0M0 8 + +
18 66 Malignant
adenocarcinoma
T3N0M0 8 + +
19 72 Malignant
adenocarcinoma
T3N0M0 9 +
20 63 Malignant
adenocarcinoma
T3N0M0 9 + +
21 59 Malignant
adenocarcinoma
T2N0M0 6 +
22 70 Malignant
adenocarcinoma
T3N0M0 7 +
23 71 Malignant
adenocarcinoma
T2N0M0 7 +
24 58 Malignant T3N0M0 9 - +
48
adenocarcinoma
25 69 Malignant
adenocarcinoma
T3N0M0 7 +
26 67 Malignant
adenocarcinoma
T3N1M0 9 +
27 70 Malignant
adenocarcinoma
T4N0M0 7 +
28 60 Malignant
adenocarcinoma
T3N0M0 9 +
29 66 Malignant
adenocarcinoma
T3N0M0 9 + +
30 73 Malignant
adenocarcinoma
T2N0M0 7
31 65 Malignant
adenocarcinoma
T4N0M0 8 + +
32 59 Malignant
adenocarcinoma
T3N0M0 9 +
33 64 Malignant
adenocarcinoma
T3N0M0 10 + +
34 71 Malignant
adenocarcinoma
T3N0M0 9
35 64 Malignant
adenocarcinoma
T2N0M0 7 +
36 68 Malignant
adenocarcinoma
T3N0M0 9 + +
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Figure 3.1: Immunohistochemical detection of WT1 in (a) normal prostate tissue and (b) prostate 
adenocarcinoma tissue.
A murine monoclonal antibody directed against amino acids 1-181 of the N terminal of the human WT1 
protein was used on a tissue array comprising duplicates of 36 cases of prostate cancer and 8 normal 
prostate tissue samples. Positive nuclear WT1 immunoreactivity is visualised as brown (arrows). Nuclei were 
counterstained with hematoxylin (blue: negative). Original magnification: x400. c: Bar graph showing the 
frequency with which prostate tissue samples showed cytoplasmic staining or additional nuclear staining.
This array also contained 8 matched samples of normal prostate tissue and 
adenocarcinoma from the same patient. Of these, all 8 normal prostate samples 
exhibited cytoplasmic staining only, as did 5 of the matched adenocarcinoma 
samples. The other 3 showed nuclear as.well as cytoplasmic staining, although this 
was not a statistically significant difference.
3.2.2 Immune responses to WT1 in patients with prostate cancer
Overall, the immunohistochemistry data demonstrates that 39% of prostate cancers 
demonstrate nuclear staining over and above the cytoplasmic staining seen in normal 
prostate tissue. The enhanced expression may result in increased WT1 peptide 
presentation in prostate cancer, facilitating T cell recognition. However, WT1 
expression in normal prostate tissue, as well as in other normal tissues, raises the 
issue of immunological tolerance to WT1. This might hinder the generation of 
effective WT1 T cell responses in vivo. Nonetheless, previous work in our laboratory 
and by others has shown that tolerance to WT1 is incomplete, as WT1 T cell 
responses can be found in patients with WT1 expressing leukaemias and solid 
tumours (160;161).
Using an HLA-A*0201/pWT126 tetramer I have characterised the T cell immune 
response to WT1 in prostate cancer patients. The HLA-A2 allele is expressed by 
approximately 40-50% of the Caucasian population, with approximately 95% of HLA- 
A2 individuals expressing the HLA-A*0201 subtype (162; 163). In pilot experiments, I 
validated the pWT126/HLA-A*0201 tetramer to determine its specificity and 
sensitivity.
3.2.2.1 Validation of the pWT126/HLA-A*0201 tetramer
3.2.2.1.1 Background staining with the tetramer in healthy controls
A panel of peripheral blood mononuclear cells (PBMC) form healthy HLA-A2-positive 
donors was used to assess the level of background staining of the tetramer reagent. 
PBMC were separated from whole blood which was obtained from the National Blood 
Service and HLA-A2 status was confirmed by anti-A2 antibody staining and FACS 
analysis. The PBMC were stained with anti-CD3 and anti-CD8 antibodies, and PI 
was used to gate out dead cells. For each PBMC sample, the same number of cells 
were stained with anti-CD3 (FITC) and anti-CD8 (APC) antibodies in the absence 
and in the presence of PE-labelled tetramer. The flow cytometric analysis of the 
sample without tetramer was used to set the quadrants such that none of the viable 
CD3+CD8+ T cells recorded as PE-positive (Figure 3.2). These quadrants were then
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Figure 3.2 FACS gating strategy:
PBMC were stained with tetramer-PE, anti-CD3 and anti-CD8 antibodies. Propidium iodide (PI), which gives a signal in 
FL2 and FL3, was then added to differentiate dead from viable cells. Cells were then analysed on an LSR-II.
(i) On the FSC/SSC dot plot, a lymphocyte gate was assigned: P1
(ii) P2 is the live lymphocyte gate: cells which stain with PI are excluded
(iii) The P3 gate includes live, CD8 positive lymphocytes
(iv) Quadrants are set on CD3/CD8 positive cells (P3) in the absence of tetramer staining such that Q2 contains 0.0%
CD3/CD8 positive cells
(v) Tetramer analysis is performed on P3. CD3 positive, tetramer positive cells are seen in Q2 and expressed as a
percentage of total CD3/CD8 positive cells (Q1+Q2).
used for the analysis of the sample stained with tetramer to record the number of 
viable CD3+CD8+ T cells that bound tetramer. The analysis of sixteen normal PBMC 
samples revealed that no more than 0.04% of viable CD3+CD8+ T cells showed 
tetramer binding (Figure 3.3). The 16 normal blood samples had tetramer 
frequencies of: 0.035%, 0.04%, 0.035%, 0.014%, 0.015%, 0.03%, 0.0%, 0.04%, 
0.0%, 0.02%, 0.04%, 0.01%, 0.01%, 0.02%, 0.03% and 0.0%, expressed as a 
percentage of live CD3/CD8 positive cells. The mean of the tetramer-positive cells 
was 0.02%, with a standard deviation of 0.015. Thus, the mean plus 2 standard 
deviations gave a value of 0.05%, which was used as a cut-off for background 
staining with the WT1-tetramer in all subsequent experiments. PBMC samples 
containing 0.05% or more tetramer binding cells were considered as positive, while 
PBMC containing less than 0.05% were negative. Using this cut-off, all PBMC from 
healthy individuals were tetramer-negative.
3.2.2.1.2 Lower limit of detection of the pWT126/HLA-A*0201 tetramer
A high avidity HLA-A2 restricted, WT1-specific T cell line that showed bright staining 
with WT1-tetramers was used in cell mixing experiments with PBMC to determine the 
sensitivity of tetramer staining (164). Decreasing numbers of WT1-specific T cells 
were added to 1x106 PBMC. Staining was performed and quadrants were set 
according to the strict criteria described above. Background staining with the tetramer 
in the PBMC population without added WT1-specific cells was 0.01% of CD3+CD8+ T 
cells (Fig 3.4, i). The mixing of WT1-specific T cells with the PBMC resulted in a 
distinct population of tetramer-positive T cells that was readily detectable when as 
few as 150 WT1 -specific T cells were added. Even when only 80 WT1-specific T 
cells were added, this resulted in increased tetramer staining from 0.01% in the 
control PBMC to 0.03% (Fig 3.4, i and ii, respectively). However, using the 0.05% 
cut-off defined above, the sample containing 80 WT1-specific T cells would be 
defined as tetramer negative. Thus, although the WT1-tetramer can identify a very 
low frequency of WT1-specific T cells, its detection limit was set at 0.05% of viable 
CD3+CD8+ T cells due to background staining in normal PBMC.
3.2.3 WT1 CTL are present in the peripheral blood of 53% patients with prostate 
cancer, but do not expand in response to peptide specific stimulation with 
IL2/IL7
Peripheral blood was obtained from 100 prostate cancer patients after obtaining 
written informed consent. Of the 100 patients, 38 were HLA-A2-positive as 
determined by flow cytometry. The clinical characteristics of these patients are listed
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Figure 3.3 Background staining with the pWT126/HLA*0201 tetramer in HLA A2 positive healthy controls
PBMC were stained with HLA-A*0201/pWT126 tetramer, anti-CD3 and anti-CD8 antibodies and propidium iodide 
(PI). Dot plots display gated CD8+ live lymphocytes. The percentage of CD8+CD3+ positive T cells that bound the 
tetramer is indicated in each plot. All PBMC samples were first stained with anti-CD3, anti-CD8 and PI in the 
absence of tetramer to set the quadrants such that no events were recorded in the top right quadrant. Following 
tetramer staining, the top right quadrant was used to record tetramer binding T cells. HLA-A2 positive PBMC from 
healthy donors (H1-H10) were stained ex vivo. In total 16 healthy donors were analysed, and the mean 
percentage of tetramer binding cells was 0.02%, with a standard deviation of 0.015. The mean plus 2 standard 
deviations (=0.05%) was used as cut off for 'background' tetramer binding.
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Figure 3.4: Validation of the pWT126/HLA-A*0201 tetramer
Mixing experiments using PBMC and a WT1-specific T cell line were used to determine the detection limit of 
WT1 tetramer staining, i) staining profile of PBMC without mixed WT1 specific T cells defined the tetramer 
background binding as 0.01%. ii-viii) show the tetramer staining profile of 106 PBMC mixed with 80-30,000 WT1- 
specific T cells. PBMC were stained with HLA-A*0201/pWT126 tetramer, anti-CD3 and anti-CD8 antibodies and 
propidium iodide (PI). Dot plots display gated CD8+ live lymphocytes. The percentage of CD8+CD3+ positive T 
cells that bound the tetramer is indicated in each plot. All PBMC samples were first stained with anti-CD3, anti- 
CD8 and PI in the absence of tetramer to set the quadrants such that no events were recorded in the top right 
quadrant. Following tetramer staining, the top right quadrant was used to record tetramer binding T cells.
in Table 3.2. Tetramer staining experiments were performed with all HLA-A2-positive 
patient samples applying the conditions that were used in the validation experiments 
described above. Figure 3.5 shows representative FACS plots of the tetramer 
staining profiles of 10 patients. Six patient samples scored positive as 0.05% or more 
of the CD3+CD8+ T cells bound the WT1-tetramer, while the remaining 4 patient 
samples did not show tetramer binding above background. In total, 20 out of 38 HLA- 
A2-positive prostate cancer patients (53%) contained detectable frequencies of 
tetramer-binding T cells. The results indicated that the frequency of WT1-tetramer 
binding cells was relatively low (range 0.05-0.6% of CD3+CD8+ T cells), and that a 
large proportion of the positive cells showed dull tetramer binding. However, the 
staining profile of some patient samples (e.g. Fig. 3.5, P5 and P6) was similar to the 
control PBMC samples that contained small numbers of added WT1 -specific T cells 
(Fig. 3.4, iii), suggesting that some patients may contain high avidity WT1 -specific T 
cells.
I explored whether it is possible to expand a population of tetramer positive cells from 
the patient samples in which tetramer-positive cells were detectable ex vivo. Patient 
peripheral blood T cells were stimulated in vitro with pWT126 peptides in the 
presence of IL2 and IL7, and stimulation with an HLA-A2-binding peptides derived 
from MelanA was used as positive control for the cell culture conditions. MelanA is a 
melanoma differentiation antigen with an unusually high T cell precursor frequency in 
the naive T-cell repertoire, allowing the in vitro generation of MelanA -specific T cells 
from naive donors (160) (165). T cell cultures from PBMC of 20 prostate cancer 
patients containing tetramer-positive cells were stimulated weekly for two rounds with 
pWT126 or pMelanA peptides. All cultures accumulated a distinct population of 
MelanA-specific T cells, demonstrating that the patients were immunocompetent and 
capable of generating peptide-specific T cell responses (Figure 3.6). However, 
although pWT126-specific T cells were detectable ex vivo, the percentage of 
tetramer positive cells did not increase after two rounds of peptide specific 
stimulation (Fig 3.7). Similar results demonstrating an accumulation of MelanA 
tetramer binding T cells, but not of WT1 tetramer binding cells were obtained with all 
20 HLA-A2-positive patient samples, suggesting a selective inability of the WT1- 
specific cells to respond to peptide stimulation. This T cell unresponsiveness 
correlated with the results of ELISPOT assays, showing that pWT126 stimulation did 
not result in peptide-specific IFNy production (Figure 3.8). Together, these data 
suggested that the WT1-specific T cells in prostate cancer patients were tolerant and 
unable to proliferate or produce IFNy in response to peptide specific stimulation.
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Table 3.2: clinical characteristics of HLA-A2 prostate cancer patients
Patient Age Stage* Prior therapy Gleason
grade**
WT1 tetramer 
(%
CD3+CD8+)
1 84 T3NxM1 Androgen ablation 0.6
2 69 T1N0M0 Radiotherapy, androgen 
ablation
8 0.06
3 78 T2N0M0 Radiotherapy, androgen 
ablation
6 0.02
4 76 T3NxM1 Radiotherapy, androgen 
ablation
7 0.05
5 60 T3N0M0 Surgery, radiotherapy 6 0.08
6 79 T3N0M0 Radiotherapy, androgen 
ablation
0.5
7 73 T2N0M0 Radiotherapy 7 0.02
8 69 T1N0M0 Radiotherapy 7 0.02
9 64 T3NxM1 Androgen ablation 0.15
10 68 T2N0M0 Radiotherapy, androgen 
ablation
6 0.03
11 64 T3NxM1 Androgen ablation 9 0.13
12 73 T2N0M0 Radiotherapy, androgen 
ablation
6 0.1
13 56 T2N0M0 Radiotherapy, androgen 
ablation
6 0.03
14 67 T2N0M0 Radiotherapy 6 0.02
15 78 T1N0M0 Androgen ablation 7 0.04
16 82 T2N0M0 Androgen ablation 7 0.04
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17 81 T3NxM0 Radiotherapy 0.04
18 67 T1N0M0 Radiotherapy 7 0.03
19 83 T2N0M0 Surgery 0.08
20 64 T2N0M0 Radiotherapy, surgery 6 0.1
21 82 T2N0M0 Surgery 7 0.6
22 68 T1N0M0 Surgery 6 0.2
23 64 T3N0M0 Radiotherapy, androgen 
ablation
7 0.08
24 71 T2N0M0 Surgery 6 0.03
25 81 T3N1M1 Androgen ablation 8 0.01
26 66 T2N0M0 Radiotherapy 0.07
27 82 T2N0M0 Radiotherapy, androgen 
ablation
7 0.07
28 80 T2N0M0 Radiotherapy, androgen 
ablation
6 0.03
29 74 T2N0M0 Radiotherapy, androgen 
ablation
7 0.01
30 69 T3N0M0 Radiotherapy 0.07
31 64 T3N1M0 Radiotherapy, androgen 
ablation
9 0.02
32 82 T3NxM1 Androgen ablation 7 0.08
33 55 T2N0M0 Radiotherapy, androgen 
ablation
6 0.03
34 73 T2N0M0 Radiotherapy 6 0.04
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35 50 T2N0M0 Radiotherapy, surgery 8 0.1
36 84 T3N1M1 Radiotherapy, androgen 
ablation
7 0.07
37 96 T3N0M0 Androgen ablation 7 0.06
38 82 T2N0M0 Androgen ablation 7 0.02
* TNM: tumour, nodes, metastases staging (Nx: information not avai able)
** Gleason: degree of differentiation seen histologically (2 scores from 0-5, with 5 
representing poorly differentiated tumours)
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Figure 3.5: WT1 tetramer staining of PBMC of prostate cancer patients
Shown are representative tetramer staining profiles of 10 patients; the percentages in bold indicate positive 
tetramer staining above background. In total 38 HLA-A2 patients were analysed, and 20 patients (53%) 
demonstrated tetramer binding (range: 0.05-0.6%). PBMC were stained with HLA-A*0201/pWT126 tetramer, 
anti-CD3 and anti-CD8 antibodies and propidium iodide (PI). Dot plots display gated CD8+ live lymphocytes. The 
percentage of CD8+CD3+ positive T cells that bound the tetramer is indicated in each plot. All PBMC samples 
were first stained with anti-CD3, anti-CD8 and PI in the absence of tetramer to set the quadrants such that no 
events were recorded in the top right quadrant. Following tetramer staining, the top right quadrant was used to 
record tetramer binding T cells
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Figure 3.6: Analysis of pMelanA responses in the peripheral blood of patients 
with prostate cancer
Shown is the analysis of 3 representative patient samples stained ex vivo and after 
each of two rounds of in vitro stimulation with pMelanA/MARHin the presence of 
IL2/IL7. PBMC were stained with tetramer-PE, anti-CD3 and anti-CD8 antibodies and 
propidium iodide (PI). Dot plots are gated onto live, CD8+ lymphocytes. Numbers 
represent the percentage of CD8+CD3+ positive cells that bound the HLA- 
A*0201/pMelanA tetramer. Quadrants were set for each experiment after collecting 
the same number of events with cells stained with anti-CD3, anti-CD8 and PI in the 
absence of tetramer. In total 20 patients were analysed, all of whom showed 
expansion of MelanA/MART1 specific T cells.
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Figure 3.7: Analysis of pWT126 responses in the peripheral blood of patients 
with prostate cancer
Tetramer staining was performed ex vivo and after each of two rounds of in vitro 
stimulation with pWT126 in the presence of IL2/IL7. PBMC were stained with tetramer- 
PE, anti-CD3 and anti-CD8 antibodies and propidium iodide (PI). Dot plots are gated 
onto live, CD8+ lymphocytes. Numbers represent the percentage of CD8+CD3+ 
positive cells that bound the HLA-A*0201/pMelanA tetramer. Quadrants were set for 
each experiment after collecting the same number of events with cells stained with 
anti-CD3, anti-CD8 and PI in the absence of tetramer. 3 representative patients are 
shown (n=20).
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Fig. 3.8. WT1-specificT cells that bind tetramer and produce IFN-y can be expanded by peptide stimulation 
with IL15, but not IL2/IL7.
(A) Patient samples which demonstrated pWT126 tetramer staining ex vivo underwent 2 rounds of in vitro stimulation 
with pWT126 and IL2/IL7 or IL15, and pMelanA/MART1 as a positive control (shown is P37). Tetramer staining was 
performed ex vivo and after each round of stimulation. The cells were stained with tetramer, PI, anti-CD8 and anti-CD3 
antibodies; the dot plots show gated viable CD8+ lymphocytes. The percentage of CD3+CD8+ cells that were tetramer 
positive is indicated in each plot. (B) ELISPOT analysis of patient T cells after one round of in vitro expansion with 
pWT126 in the presence of IL2/IL7 or IL15 (phenotype indicated by red rectangle). T cells were stimulated overnight 
with autologous PBMC in the presence or absence of pWT126 peptides. As a positive control, T cell stimulation was 
performed with autologous PBMC and SEB. Negative control: responder T cells only. (C) The ELISPOT results are 
illustrated in a column graph (SFU: spot forming units).
3.2.4 The unresponsive phenotype of WT1-specific T cells can be reversed by 
in vitro culture with IL15
It has previously been shown in a murine model that tolerance of tumour antigen- 
specific CD8+ T cells was reversible by ex vivo culture in the presence of IL15 (159). I 
therefore investigated whether IL15 was able to rescue the expansion and IFNy 
production of WT1-specific T cells from the blood of prostate cancer patients.
I had sufficient PBMC from 8 HLA-A2-positive patients, which had demonstrated 
positive pWT126 tetramer staining, to set up stimulation cultures with pWT126 in the 
presence of IL2/IL7 as previously, and in the presence of IL15. The PBMC were also 
stimulated with pMelanA as a positive control. As in previous experiments, all 
patients generated a distinct population of cells which bound pMelanA tetramer. In 
3/8 patients, culture with pWT126 and IL15 resulted in an increase in the frequency 
of WT1-tetramer binding cells (Fig 3.8). The accumulation of tetramer binding T cells 
in cultures supplemented with IL15 correlated with the detection of pWT126-specific 
IFNy production using ELISPOT assays (Fig 3.8). As expected, the T cells from the 
cultures stimulated in the presence of IL2/IL7 did not display pWT126-specific IFNy 
production in the ELISPOT analysis, although stimulation with the positive control 
SEB demonstrated that these T cells produced similar numbers of IFNy spots as 
seen with T cells from the IL15 cultures. To exclude these results being a result of in 
vitro priming of naive T cells in the presence of IL15, the experiment was repeated 
with 5 patient samples that did not bind WT1 tetramer ex vivo. All five patients failed 
to expand a population of WT1 CTL in the presence of IL2/IL7 or IL15, although all 
patients accumulated a population of Melan A tetramer binding T cells (Fig 3.9).
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Figure 3.9: patients in which pWT126-specific T cells were not detected ex vivo did 
not expand a population of tetramer binding cells following in vitro culture with 
either IL-2/IL-7 or IL-15. Patient samples which did not demonstrate pWT126 tetramer 
staining ex vivo underwent 2 rounds of in vitro stimulation with pWT126 and IL2/ IL7 or 
IL15. Antigen stimulation with pMelan A was used as a positive control for cell culture 
conditions. Tetramer staining was performed ex vivo and after each round of stimulation: 
cells were stained with PE-labelled tetramer, propidium iodide, anti-CD8 and anti-CD3 
antibodies and analysed by flow cytometry. The FACS plots display gated viable CD8+ 
lymphocytes. Figures represent the percentage of viable CD3+CD8+ cells that are 
tetramer positive. Representative results from one patient (P32) are shown (n=5 
patients). pMelan-A-specific T cells were detectable, after 2 rounds of peptide-specific 
stimulation, in all samples.
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3.3 Discussion
The IHC data presented here demonstrated nuclear WT1 expression in 39% (14/36) 
of prostate cancer samples, but not in normal prostate tissue. Similar results were 
recently reported by Nakatsuka et al, who found that 6/24 prostate cancer samples 
(25%) demonstrated nuclear as well as cytoplasmic WT1 staining, although they did 
not stain normal prostate tissue for comparison (166). In addition, Devilard et al have 
described nuclear WT1 expression in 44/85 (52%) of prostate cancer samples, and 
also demonstrated that WT1 expression was more frequent in more advanced T3 
cancers (which extend through the prostate capsule) compared to T2 cancers (which 
are enclosed within the capsule) (167). This is consistent with my study findings, 
which showed that 14 out of 29 T3/T4 cancers showed nuclear WT1 expression, 
whilst all seven T2 cancers were negative for nuclear WT1 expression.
The great advantage of IHC is the ability to demonstrate where a protein is located 
within the tissue examined. Variable patterns of nuclear or cytoplasmic staining are 
characteristic of different tumour types (166). For example, WT1 IHC performed on a 
range of paediatric tumours found that whereas 11/11 cases of rhabdomyosarcoma 
(RMS) demonstrated strong cytoplasmic staining, Wilms' tumours had a variable 
nuclear and/or cytoplasmic positivity in 17/24 cases, and strong nuclear staining was 
seen in 2 lymphoblastic lymphomas (168). To illustrate that cytoplasmic staining did 
not represent non specific antibody binding, the cytoplasmic WT1 staining specificity 
in RMS was also confirmed by Western blot analysis and RT-PCR.
WT1 expression in normal prostate epithelial cells was shown to be confined to the 
cytoplasm, suggesting that the regulation of WT1 is altered in prostate cancer. A 
recent study has also described cytoplasmic WT1 expression in normal lung 
epithelial cells (169). In this case, the exposure of lung epithelial cells to inflammatory 
cytokines such as tumour necrosis factor alpha (TNFa) resulted in the translocation 
of WT1 from the nucleus to the cytosol. Phosphorylation of residues in the zinc finger 
domain of WT1 protein by protein kinase A was shown to disrupt DNA binding and 
result in the cytoplasmic accumulation of WT1 (170; 171). Although WT1 was 
originally described as a nuclear transcription factor, it has more recently been shown 
to shuttle between the nucleus and the cytoplasm, and it has been suggested that 
WT1 also plays a role in post-transcriptional regulation (172). Structural modeling has 
revealed a potential RNA recognition site in the N-terminus of WT1 (173), and it was 
also demonstrated that the zinc-finger domain in the C-terminal part of WT1 could
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bind to RNA (174). In addition, cytoplasmic WT1 is present within ribonucleoprotein 
particle (RNP) complexes, and is associated with ribosomes and actively translating 
polysomes. This data lends weight to the idea that WT1 also plays a role in post- 
transcriptional processes (172).
The WT1 gene products exist in over 25 isoforms. These have a range of functions 
and may act as an activator or repressor of genes under different circumstances. 
There are a number of mechanisms by which the function of the WT1 protein may be 
modulated, including phosphorylation, dimerization and alternative splicing. In 
mammals, exons 5 and 9 of WT1 are alternatively spliced, giving rise to four different 
splice isoforms (103; 175). The +KTS/-KTS ratio has been shown to be strongly 
conserved (176). The importance of the ratios is demonstrated in Frasier syndrome, 
which results from a mutation in the splice donor site in intron 9 of one WT1 allele, 
resulting in the loss of expression of the WT1+KTS form of one allele (177). The 
change in ratio of +KTS/-KTS is responsible for the severe developmental defects in 
this disease. Silberstein et al have also demonstrated that the proportion of different 
splice variants was different in breast cancer samples compared to normal breast 
tissue, suggesting a mechanism for WT1’s involvement in breast cancer 
development through altered WT1 isoform ratios (178)
The role of WT1 in the oncogenesis of prostate cancer has yet to be established. 
However, it is known that WT 1 interacts with prostate apoptosis response gene, Par4 
(179). Furthermore, Cheema et al demonstrated in prostate cancer cell lines that 
Par4 regulates proto-oncogene bcl-2 expression through a WT1 binding site on the 
bcl-2 promoter; bcl-2 being known to be associated with the development of 
androgen resistance in prostate cancer (180). They observed decreased bcl-2 
expression in prostate cancer cell lines in response to treatment with all trans-retinoic 
acid (ATRA) associated with a rise in WT1 expression, and also showed that bcl-2 
expression could be increased by blocking WT1. However, WT1 is known to bind to 
two different regions on the bcl-2 promoter, and can regulate bcl-2 transcription by 
acting as either an activator or a repressor (181) (182), so it is not yet clear how 
these in vitro results relate to the physiological situation. The suggestion that the loss 
of WT1 correlates with the development of androgen resistance also contradicts data 
presented by Devilard et al, who report that WT1 gene expression levels were 
associated with androgen independent prostate cancer in human prostate cancer 
samples (167).
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While the advantage of immunohistochemistry is the ability to demonstrate the 
location of the protein under investigation, this technique also has a number of 
limitations. Firstly, immunohistochemistry is not quantitative. Although researchers 
can assign a figure from 0 (no staining) to 3 (very strong staining), this itself is 
subjective and researcher dependent. Tissue handling and fixation techniques can 
also affect the quality of the samples and the sensitivity of subsequent IHC assays. 
Western Blot is another method of measuring protein levels which is semi- 
quantitative. An alternative, quantitative, assay to measure WT1 expression is real­
time PCR, whereby the amount of mRNA is determined by comparing the results to a 
standard curve produced by performing PCR on known amounts of DNA.
A further issue with immunohistochemistry is that of antibody cross reactivity. The 
staining protocol therefore includes several important controls. When the antibody 
was validated, skeletal muscle was used as a negative control. As a further negative 
control, the primary antibody is replaced with assay diluent, to exclude non-specific 
binding by the secondary antibody or other reagents. It was previously thought that 
cytoplasmic immunohistochemistry staining might represent non specific antibody 
binding, but it has since been shown that WT1 cytoplasmic staining correlates with 
Western Blot and RT-PCR data (167;168). In addition, in my series of prostate 
cancer samples there are samples which do not stain in the cytoplasm or the 
nucleus, which act as an internal negative control, since one would expect any cross 
reactivity to be present in all prostate samples. Whether or not the cytoplasmic WT 1 
staining of normal prostate tissue seen in Figure 3.1 represents true staining or non 
specific staining may have implications for toxicity to normal prostate tissue that 
might result from immunotherapeutic strategies which target WT1. This could be 
further investigated by Western Blot or RT-PCR analysis of normal prostate tissue, to 
look for WT1 protein or mRNA, respectively.
The majority of peptides presented by MHC Class I molecules are derived from 
cytosolic or nuclear proteins. In those cases where prostate cancer cells express 
WT1 in the nucleus in addition to that seen in the cytoplasm, this may result in 
increased presentation of WT1 peptides on the surface of these prostate cancer 
cells, which could facilitate T cell recognition. However, to address this, mass- 
spectrometry and sequence analysis of peptides eluted from fresh tumour material 
would be required (183).
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I found a low frequency of WT1-tetramer binding T cells in 53% of prostate cancer 
patients, suggesting that tumour cells had stimulated autologous T cell responses. It 
would have been interesting to correlate IHC staining with WT1 tetramer staining for 
individual patients. However, we did not have ethical approval for this. Furthermore, 
the original tissue blocks were often not available, since the majority of patients had 
been diagnosed elsewhere before being referred for radiotherapy.
My data is consistent with previously published literature reporting a low frequency of 
VVT1 -specific T cells in patients with WT1-expressing malignancies. Oka et al 
reported ex vivo tetramer staining in 2 breast cancer and 8 lung cancer patients, with 
a range of 0.08-1.31% of CD8s (116; 160). Studies in leukaemia patients have 
demonstrated the presence of IFNy-producing WT1-specific T cells in the peripheral 
blood (161 ;184). Why some patients possess WT1 CTL which bind tetramer, while 
others do not, is not well understood. There is increasing data that tetramer staining 
can occur in the absence of effector function, and vice versa (150;157;185;186). WT1 
CTL may be present in the peripheral blood of prostate cancer patients at too low a 
frequency to be detected by tetramer staining. Rezvani et al used quantitative PCR to 
measure IFN-T mRNA production in response to peptide stimulation as a surrogate 
for the presence of antigen specific CTL. They found this method to be approximately 
10 times more sensitive than tetramer staining, and were able to detect pWT126- 
specific responses ex vivo in the peripheral blood of patients with chronic 
myelogenous leukaemia as well as that of healthy HLA-A2-positive blood donors 
(184).
Clinical studies have demonstrated that WT1-specific T cells are detectable in 
patients, and that they are associated with anti-tumour effects after vaccination and 
after allogeneic transplantation. An increase in the frequency of WT1-specific T cells 
following allogeneic stem cell transplantation correlated with a decrease in WT1 
transcript frequency in the peripheral blood of leukaemia patients, suggesting that 
WT1-specific CTL contributed to a reduction in the number of WT1 expressing 
leukaemia cells (187). Further evidence for the anti-tumour effect of WT1-specific 
CTL has been obtained in vaccination studies in patients with leukaemia and solid 
tumours. A correlation was found between vaccine induced T cell responses and a 
reduction in tumour burden, tumour markers or WT1 transcript numbers (116;188). 
Conversely, the loss of WT1-specific T cells was shown to correlate with the 
reappearance of WT1 expressing leukaemia cells (196).
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However, in my study, the naturally occurring WT1 specific T cells in prostate cancer 
patients were functionally impaired and unable to expand upon WT1 -peptide 
stimulation in the presence of IL2 and IL7. A similar observation was made recently 
in patients with leukaemia, when naturally occurring WT1-specific T cells failed to 
expand upon WT1 -peptide stimulation in the presence of IL2 and IL7. In this study, 
the removal of the CD4+CD25+ T cell population restored the ability of WT1-specific 
T cells to expand (189). In my study, IL15 was able to restore the functional activity of 
WT1-specific T cells in 3 out of 8 patients tested. It is possible that regulatory 
CD4+CD25+ T cells were responsible for T cell suppression in those patients that did 
not respond to IL15.
The induction of T cell unresponsiveness has been described in melanoma patients 
and in murine tumour models (12; 156;157). Although immunogenic tumours 
stimulated antigen-specific T cell responses, these T cells were rendered non­
functional and unable to control tumour growth (12). In another study the adoptive 
transfer of T cells initially resulted in tumour regression, but this was followed by 
progressive tumour growth associated with the induction of unresponsiveness in the 
transferred T cells (190). There are extensive reports of T cells isolated from patients 
with tumours being functionally impaired (191). In such cases, tetramer staining may 
not correlate with the presence of functional cells and may be misleading in cancer 
patients, where tumour antigen specific T cells have been subject to peripheral 
tolerance mechanisms.
Considering the similarity of the cytokine receptors for IL2 and IL15, it is surprising 
that IL15 restored the functional activity of tolerant T cells that did not respond to IL2. 
The IL15 receptor is one of at least six different interleukin receptors (IL2, IL-4, IL7, 
IL-9, IL15 and IL21) to which the gamma chain (yc) (CD 132) cytokine receptor sub­
unit is common. In addition, the receptor complexes for IL2 and IL15 both share a (3 
(CD122) subunit, forming a medium affinity f3yc receptor which results in functional 
overlap of IL2 and IL15, such as stimulating T cell proliferation (192; 193). However, 
each cytokine also binds to a unique a chain which forms a high affinity receptor 
complex with the (3yc complex, giving rise to the different roles each cytokine plays in 
T cell biology (194). Signalling via the IL2 receptor a (Ra) (CD25) can result in 
activation induced cell death (195) and inhibit memory cell proliferation and survival 
(196), whereas signalling through the IL15 Ra complex is required for the 
development of components of the innate immune system, and for the maintenance 
of memory CD8 T cells (197;198). The IL15 Ra is the likely candidate for mediating
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the effects seen with IL15 in this study, although the intracellular signalling pathways 
that lead to distinct biological responses upon IL2 and IL15 binding are currently not 
fully understood. In classical T cell anergy, IL2 was very effective in reversing T cell 
unresponsiveness (158). However, recent experiments in transgenic mice revealed 
that tolerance of T cells specific for a tumour-associated model antigen was reversed 
by IL15, but not IL2 (159). This study in prostate cancer patients is the first 
description of a similar situation in humans, where T cells specific for a tumour- 
associated antigen are unresponsive to IL2, but recover functional activity when 
stimulated in the presence of IL15. IL2 is routinely used to enhance the functional 
activity of adoptively transferred tumour-reactive T cells in vivo at present. The data 
described here raises the possibility that IL15 may promote T cell function in those 
patients who do not respond to treatment with IL2.
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Chapter 4: The effect of additional CD3 on endogenous TCR expression in
58a'p- cells
4.1 Introduction
Retroviral TCR gene transfer is an attractive strategy by which large numbers of 
antigen specific T cells can be generated for adoptive transfer (133; 135; 199-202). 
One of the advantages of this technique is that it can be used to circumvent possible 
impairment of autologous T cell responses against tumour associated antigens, since 
central tolerance is bypassed. In addition, the introduced TCR specificity can be 
targeted against poorly immunogenic targets and a high avidity TCR can be selected 
for transfer. This method has recently seen success in the first clinical trial of TCR 
gene therapy, where MART 1 specific T cells - generated by retroviral gene transfer - 
were adoptively transferred into patients with metastatic melanoma. The engineered 
T cells engrafted in 15 out of 17 patients, 2 of whom demonstrated long term tumour 
regression (137).
Since the density of TCRs on the surface of cells affects their functional avidity, there 
are a number of factors which may affect the success of this technique (203;204). 
Several different strategies have been developed to increase expression of the 
introduced T tR  by manipulating its structure, for example by murinising the constant 
domains of the a and (3 chains, by introducing an additional disulphide bond into the 
constant regions of the introduced TCR (150;205;206). More recently, a and p chains 
have each been linked to the CD3£ chain, which results in increased preferential 
pairing of TCR chains in the Jurkat T cell line.
TCR alpha and beta chains must assemble with the CD3 complex in order for the 
TCR to be expressed on the cell surface. The CD3 complex is comprised of 4 
invariant chains: gamma, delta, epsilon and zeta. One epsilon and one delta chain 
form a largely extracellular heterodimer, as do one gamma and one epsilon chain, 
whereas two zeta chains form a homodimer which is largely intracellular. The TCR 
and CD3 chains assemble separately in the ER before coming together to form the 
TCR/CD3 complex (Figure 4.1). The zeta chains are the last component to be 
integrated before the complex is transport to the cell surface (122-124).
At present it is unclear whether TCR and CD3 components are present in equimolar 
. concentrations in T cells, or whether one is in excess. It may be that TCRs,
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Figure 4.1: Assembly of the TCR/CD3 complex, a+b): The TCR a and p chains are transcribed and form a heterodimer 
in the endoplasmic reticulum, separately from the CD3£, 6, e and y chains, c) The TCR:CD3 complex subsequently 
assembles within the ER, with the CD3£ chain being the last component to be integrated (d) before the complex is 
transported to the cell surface (e). Only complete TCR/CD3 complexes are displayed on the cell surface. Partially 
assembled TCRs are retained in the ER or targeted for degradation. It is not clear whether TCR and CD3 chains are 
produced in equimolar concentrations, or whether one of the two is in excess.
introduced by retroviral gene transfer, are expressed because there is an excess of 
CD3 molecules for them to assemble with. Conversely, it could be that there is an 
excess of endogenous TCR chains, and that CD3 is rate limiting, but exogenous 
TCRs can still be expressed if they fold efficiently and out-compete endogenous TCR 
chains for association with CD3 molecules. If the latter is the case, then one would 
predict that the effect of providing additional CD3 would be to increase TCR 
expression.
The aim of this chapter is to investigate whether TCR expression can be increased 
by co-transduction with the genes encoding the CD3 complex. To address this 
question I performed experiments in 58ap' cells: a lymphoma cell line which 
expresses endogenous CD3, but no endogenous TCR chains. I have also explored 
whether increased TCR expression correlates with increased antigen specific 
cytokine production or sensitivity.
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4.2 Results
4.2.1 CD3 is rate limiting for TCR expression in 58a p'cells
Initial experiments were performed in the 58a‘p' cell line, a murine lymphoma cell line 
that expresses CD3, but no TCR a or (3 chains. Consequently, neither CD3 
molecules nor TCR molecules are detectable on the surface of 58a‘p- cells. The 
introduction of TCR a and (3 genes results in the assembly of TCR/CD3 complexes, 
which are expressed on the cell surface. I have explored whether the introduction of 
additional CD3 molecules can enhance TCR expression in this model system.
A schematic representation of the retroviral vectors used in these experiments can 
be found in Figure 4.2. The F5 TCR recognises a peptide from the nuclear protein of 
influenza, pNP366, in the context of H2-Db Class I molecules. The WT1 TCR 
recognises a peptide from the human WT1 protein (pWT126) in the context of HLA- 
A*0201 Class I molecules. The WT1 TCR used in these experiments is a hybrid 
comprised of murine constant domains and human variable domains and is 
expressed in both murine and human cells. I have used this TCR because it is being 
investigated in the human system in the laboratory at present, and recent work has 
demonstrated that this hybrid WT1 TCR shows increased expression and tetramer 
binding in human T cells compared to the wild type, fully human WT1 TCR (150).
58a‘p‘ cells were transduced with a TCR alone or with additional CD3, using a 
retroviral construct containing the 4 CD3 chains in addition to GFP, hereafter referred 
to as CD35-GPF (Figure 4.2). GFP was then used to differentiate cells expressing 
only endogenous CD3 (GFP negative) from cells expressing additional exogenous 
CD3 (GFP positive). This set of experiments was repeated using the F5 TCR and the 
WT1 TCR. F5 TCR expression was assessed using the anti-V(3-11 antibody and 
tetramer, WT1 TCR expression was assessed using the anti-V(3-2.1 antibody and 
tetramer. 58a p‘ cells were mock transduced as a control. As an additional control, 
58a'p' cells were transduced with a retroviral GFP construct (hereafter referred to as 
GFP control) which contains the WT1 gene in reverse orientation, and from which 
only the GFP is expressed (Fig 4.2, d). The GFP control is required for flow 
cytometry to exclude the effects of GFP bleeding into the PE channel.
Mock transduced 58a p‘ cells did not express surface CD3, V(3-11 or bind tetramer 
(Figure 4.3, a-d). After transduction with F5 TCR alone, 78% of 58a p' cells were Vf3- 
11 positive and 37% bound tetramer, with an MFI of 1940 and 2277, respectively.
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Figure 4.2 Schematic representation of retroviral vectors
The F5 TCR vector is based on Moloney murine leukaemia virus. The F5 TCR recognises an epitope from the 
influenza protein presented by H2Db and the a and (3 chains are linked by an IRES. The WT1 TCR is a 
myeloproliferative sarcoma virus based vector. The WT1 TCR recognises the pWT126 peptide from the human 
WT1 protein in the context of HLA-A*0201 Class I molecules. The constant domains of the a and (3 chains have 
been replaced with murine TCR constant (mC) domains, mutated to contain additional cysteine residues which 
form an additional disulphide bond between the TCR chains. V: variable region, c: constant region. This vector 
uses a viral 2A sequence to link the a and (3 chains, and has also been codon optimised. The CD35-GFP vector is 
a murine stem cell virus based vector, containing the CD3 chains, linked by 2A sequences, in the order S,y,£ then 
This vector is also linked to a green fluorescent protein (GFP) marker by an internal ribosome entry site (IRES). 
The GFP control vector uses the same long terminal repeat (LTR) as the WT1 TCR vector and contains the WT1 
gene inserted in reverse orientation (such that this gene is not translated), followed by IRES GFP (not codon 
optimized).
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Figure 4.3. Surface staining of 58a p‘ cells transduced with the F5 TCR 
alone, with additional CD36-GFP or with GFP control.
58a-(3- cells unstained, stained with anti CD3-PE, anti V(311-PE and tetramer-PE. 
Figures in bold indicate the increase in antibody staining mean fluorescense intensity 
from Q1 to Q2. a-d): mock transduced; e-h): transduced with the F5 TCR ; i-l): 
transduced with the F5 TCR and CD36-GFP; m-p): 58a-(3- cells transduced with 
F5 TCR and GFP construct as a control. Representative results from one experiment 
are shown (n=8)
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58a'p' cells transduced with F5 plus additional CD3 showed that the higher the CD3- 
GFP signal, the higher the surface expression of CD3 and Vf3-11, and tetramer 
binding was also increased (Fig 4.3, j-l). Within the same FACS plot it can be 
demonstrated that cells in quadrant 2, transduced with CD3 as well as F5 TCR, 
express more TCR than cells in quadrant 1, transduced with the TCR alone. The 
mean fluorescence intensity of Vp-11 staining was 1745 for cells transduced with F5 
and 6376 for cells transduced with F5 plus CD35-GFP; a 3.7 fold increase (Fig 4.3, 
k). Tetramer staining MFI shows a corresponding increase from 1794 to 4945: a 2.8 
fold increase (Fig 4.3,1).
One explanation for this could be that double transduced cells might have taken up 
more DNA than cells transduced with only the TCR vector, and that this data 
represented cells containing a high copy number of the F5 vector. To exclude this, I 
transduced cells with F5 TCR and the GFP control vector. The increase in V(3-11 MFI 
between F5 transduced cells (1438) and F5 plus GFP control transduced cells (1783) 
was 1.2 fold (Fig 4.3, o). The corresponding rise in tetramer staining MFI was from 
1711 to 2079: also a 1.2 fold increase (p). This indicates the co-transfer of TCR and 
GFP control vector resulted in only small increases in TCR expression. In contrast, 
co-transfer of TCR and the CD35-GFP vector led to more than a 3 fold increase in 
TCR expression, indicating that endogenous CD3 was limiting for F5 TCR expression 
in 58o p‘ cells.
Similar results were obtained with the WT1 TCR. 58°'^ cells were transduced with 
the WT1 TCR alone or with additional CD35-GFP. WT1 TCR expression was 
assessed using the anti-V(3-2.1 antibody and the pWT126/HLA-A*0201 tetramer. As 
controls, 58a‘p‘ cells were mock transduced and also transduced with the GFP control 
vector as above. Mock transduced 58a p' cells did not express surface CD3, V(3-2.1 
or bind tetramer (Fig 4.4, a-d). After transduction with WT1 TCR alone, 79% of 58a p' 
cells were V(3-2.1 positive, but only 0.2% bound pWT126/HLA-A*0201 tetramer (Fig 
4.4; g, h). 58a'p' cells transduced with WT1 TCR plus additional CD3 again showed 
that the higher the CD36-GFP signal, the higher the surface expression of CD3 and 
VJ3-2.1, and pWT126/HLA-A*0201 tetramer binding was also increased (Fig 4.4, j-l). 
The mean fluorescence intensity of Vp-2.1 staining was 457 for cells transduced with 
WT1 TCR and 1715 for cells transduced with WT1 plus CD3: a 3.8 fold increase (Fig 
4.4, k). WT1 tetramer MFI shows a corresponding increase from 160 to 361: a 2.2 
fold increase (Fig 4.4, I). Hence, cells transduced with CD3 as well as WT1 TCR 
express more TCR than cells transduced with the WT1 TCR alone. The GFP control
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Figure 4.4. Surface staining of 58a p' cells transduced with the WT1 TCR 
alone or with additional CD3. 58a-(3- cells unstained, stained with anti CD3-PE, 
anti VJ32.1-PE and tetramer-PE. Figures in bold indicate the increase in 
antibody staining mean fluorescense intensity from Q1 to Q2. a-d): mock 
transduced; e-h): transduced with WT1 TCR ; i-l): transduced with the WT1 
TCR and CD35-GFP; m-p): 58a-f3- cells transduced with WT1 TCR and GFP 
construct as a control. Representative results from one experiment are shown (n=8)
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again demonstrates that the increase in MFI is due to additional CD3: a 1.1 fold 
increase in V(3-2.1 MFI was seen between WT1 TCR transduced cells (428) and 
WT1 TCR plus GFP control transduced cells (477; Figure 4.4, o). This data 
demonstrates that co transduction of CD3 results in increased expression of the WT1 
TCR in 58a'p‘ cells. In addition, the WT1 TCR is seen to bind tetramer at a higher 
frequency in the presence of additional CD3, when the density of TCRs on the cell 
surface is greater.
4.2.2. Increased TCR expression does not correlate with an increase in antigen 
specific cytokine production or increased sensitivity
I investigated whether increased TCR expression following co-transduction of TCR 
and CD3 genes correlated with enhanced antigen specific function in 58a'p' cells. 
Cytokine production by bulk transduced cells was measured using an ELISA. Both 
F5 and F5 plus CD35-GFP transduced cells produced IL-2 in response to antigen 
specific stimulation (Figure 4.5). However, contrary to expectation, F5 TCR+CD35- 
GFP transduced cells, expressing higher levels of TCR, produced less IL-2 at each 
peptide concentration. There was no detectable difference in sensitivity between the 
two groups. Similar results were obtained when F5 TCR + CD35-GFP cells were 
sorted by FACS into two populations: Vp11 only expressing cells and Vp11+GFP 
expressing cells. The phenotype of these cells is shown in Figure 4.6. Again, IL2 
production by TCR/CD3 high sorted cells was inferior to IL2 production by TCR only 
expressing, sorted cells (Fig 4.6). This data suggested that 58a‘p‘ cells transduced 
with the F5 TCR and CD3 genes were functionally inferior to cells transduced with 
the TCR alone.
4.2.3 Decreased cytokine production in TCR high ceils is not due to increased 
apoptosis.
I went on to explore the mechanism underlying the decreased cytokine production 
seen in 58ap' cells expressing high CD3 and TCR levels. The signal delivered 
through the TCR plays an important role in determining T cell fates, such as 
activation, proliferation, anergy and apoptosis (207-209). Peripheral T cell death is 
required to control T cell expansion and to eliminate cells following the induction of 
an effective immune response (210). One mechanism by which this occurs is 
activation induced cell death (AICD), in which activation via the TCR results in 
apoptosis (209). The nature and intensity of TCR signalling are among the factors 
that determine the occurrence of AICD. I therefore investigated whether CD3/TCR 
high cells were being driven into apoptosis upon ligation of the TCR.
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Figure 4.5: IL2 production by F5 TCR and F5 TCR+CD35-GFP transduced 58a p' cells. Bulk transduced F5 
TCR and F5 TCR+CD35-GFP cells were stimulated for 24 hours with RMA-S cells loaded with relevant (NP366) 
or irrelevant (pSV9) peptides. Tenfold dilutions of relevant peptide were used (10pM-1nM). Supernatant was 
harvested as assessed for IL2 production by ELISA. Shown is the mean IL2 concentration (pg/ml) +/- standard 
deviation of triplicate values. Representative data is shown from 5 repeat experiments. The phenotype of the 
cells used is shown in Figure 4.3
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Figure 4.6: IL2 production by F5 TCR and F5 TCR+CD36-GFP transduced, sorted 58ap' cells. 
A: phenotype of sorted (i) F5 TCR and (ii) F5 TCR+CD35-GFP transduced 58a P‘ cells stained with anti-Vpil 
antibody.
B: Sorted F5 TCR and F5 TCR+CD35-GFP transduced cells were stimulated for 24 hours with RMA-S cells loaded 
with relevant (NP366) or irrelevant (pSV9) peptides. Tenfold dilutions of relevant peptide were used (10pM-1nM). 
Supernatant was harvested as assessed for IL2 production by ELISA. Shown is the mean IL2 concentration (pg/ml) 
+/- standard deviation of triplicate values. Representative data is shown from 5 repeat experiments.
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When cells undergo apoptosis, negatively charged phosphatidylserine groups which 
normally reside on the interior side of the cell membrane are transported to the outer 
surface of the cell. Phagocytic cells recognise apoptotic cells by the presence of 
these negatively charged phospholipids. Annexin V also binds to these 
phosphatidylserine groups on cell membranes and can be used to identify cells at an 
early stage in apoptosis. Propidium iodide (PI) is an intercalating agent which is 
taken up by dead cells, both apoptotic and necrotic, but is membrane impermeant 
and not taken up by viable cells. Combining Annexin V and PI staining reveals cells 
which are at an early stage of apoptosis (stain with Annexin V only) or in late 
apoptosis (stain with both Annexin V and PI).
Figure 4.7 demonstrates that CD3/TCR high cells were not being driven into 
apoptosis more frequently than CD3/TCR low cells. Background levels of apoptosis 
when cells were stimulated with the irrelevant peptide pSV9 were 1.2% and 2.0% for 
TCR low (P2) and CD3/TCR high cells (P3), respectively (Fig 4.7; b) i & ii). Upon 
stimulation with relevant peptide pNP366, the increase in apoptosis was 2% and 
1.4%, respectively.
4.2.4 Increased TCR expression and tetramer binding is seen following co­
transduction with TCR chains plus the CD3£-GFP vector
Correct assembly of the TCR/CD3 complex is required in order for signal 
transduction to occur following antigen recognition by the TCR. I hypothesized that 
the TCR/CD3 high cells produced less IL2 than their TCR only transduced 
counterparts because of incorrect assembly of the TCR/CD3 complex. CD3 chains 
are present in the TCR/CD3 complex at a ratio of 2:2:1:1 for e,£,5 and y, respectively. 
The CD36 vector was constructed using viral self cleaving 2A sequences to link the 
four CD3 chain genes (149). Theoretically, the entire cassette should be translated 
as a single ribosomal event, with all four chains being produced in equimolar 
quantities. However, it is possible that the proximal genes are translated at a higher 
frequency than distal genes. This may result in CD3 zeta chains being translated at a 
disproportionately low frequency to that required for assembly of the fully functional 
TCR/CD3 complex. Furthermore, as the CD3 zeta chain exists as a homodimer, 
twice as many zeta chains are required compared to, for example the delta chain. If 
the genes at the beginning of the CD3 cassette were translated at a higher frequency 
than the £ and £ genes at the end of the cassette, there would be a relative excess of 
6 and y chains, which might favour the expression of functionally inferior TCR/CD3 
complexes lacking the homodimer. The CD3 £ chain plays a key role in
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Figure 4.7: Annexin V staining of stimulated F5/CD36-GFP transduced 58a p‘ cells
A: FACS plot demonstrating gating of P2: TCR low, GFP-ve cells; and P3: TCR high, CD3-GFP high cells.
B: Annexin V/PI staining of P2 and P3 after culture for 24 hours with RMA-S cells loaded with relevant (pNP366) 
and irrelevant (pSV9) peptides. Figures indicate the percentage of cells which stained with Annexin V only
receptor assembly, expression and signalling. Downregulation of Z, chain expression 
and impairment of T cell function has been demonstrated in T cells isolated from 
hosts with chronic inflammatory diseases including viral infections, cancers and 
autoimmune disease (reviewed in (211)). To test this hypothesis, I redesigned the 
CD3 vector with the £ and £ chains at the beginning of the cassette, using the same 
2A sequences to link the genes as in the original vector. The CD3 chains were also 
codon optimised, since this has been shown to increase expression of TCR genes 
(151). A schematic of the CD3£-GFP vector is shown in Figure 4.8.
58a‘p' cells were transduced with the F5 TCR alone, F5 TCR plus CD36-GFP, F5 
TCR plus CD3£-GFP or F5 TCR plus GFP control. F5 TCR expression was assessed 
using anti-V(3-11 antibody and tetramer as previously. Co-transduction with the F5 
TCR and CD35-GFP vector resulted in a 2.3 fold increase in both V(311 and tetramer 
staining MFI (Fig 4.9; e,f). Co-transduction with the F5 TCR and CD3£-GFP vector 
resulted in a 5.4 fold increase in Vf311 staining MFI (from 1199 to 6431) and a 4.3 
fold increase tetramer binding compared to cells transduced with the TCR alone (Fig 
4.9; h,i). Again, co-transduction with F5 TCR and the GFP control vector only 
marginally increased V|311 staining and tetramer binding by 1.1 and 1.2 fold, 
respectively (Fig 4.9; k,l). Of note, the increase in CD3, Vf311 and tetramer binding 
seen with the CD3£-GFP vector was consistently several orders of magnitude higher 
than that seen with the CD35-GFP vector in repeat experiments.
Similar results were observed when this experiment was repeated with the WT1 
TCR. 58a"p' cells transduced with the TCR + CD3£-GFP vector showed a 16 fold 
increase in V(32.1 staining (from 671 to 10,427) and a 20 fold increase in tetramer 
MFI (from 489 to 9930) compared to cells transduced with the TCR alone (Fig 4.10; 
k,l). This was compared to a 1.9 and 1.3 fold increase in V(32.1 and tetramer staining, 
respectively, in cells transduced with WT1 TCR and CD35-GFP (Fig 4.10; g,h). The 
corresponding increase in MFI for cells transduced with WT1 TCR and GFP control 
vector was 0.9 fold for both Vp2.1 staining and tetramer binding (Fig 4.10; o,p). Of 
note, the increase in WT1 TCR expression in the presence of additional CD3£-GFP 
was consistently higher than that seen with the F5 TCR in repeat experiments.
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CD36-GFP
5’ LTR - CD35 2A CD3y 2A CD3t 2A CD3< —  IRES GFP —  3’ LTR
CD3S-GFP
5’ LTR — \
'
2A CD3t 2A CD36 2 A CD3y IRES GFP 3’ LTR
Figure 4.8: a new CD3 vector design
In the CD3£-GFP construct, the four CD3 chains are linked by the same 2A sequences as the CD38-GFP 
construct, but the order of the CD3 chains has been changed. The CD35-GFP construct is based on murine stem 
cell virus, whereas the CD3£-GFP vector uses the myoproliferative sarcoma virus LTR, and has also been codon 
optimized.
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Figure 4.9. Surface staining of 58ap- cells transduced with the F5 TCR 
alone, with additional CD36-GFP, with additional CD35-GFP or with GFP control 
vector.
After transduction, 58a-p- cells were stained with anti Vp11-PE and tetramer-PE. 
Figures indicate the MFI of antibody staining in Q2 as a multiple of the antibody staining 
in Q1 (e.g.: x2.3 indicates a 2.3 fold increase in MFI from Q1 to Q2). a-c): 58a-(3- cells 
transduced with the F5 TCR; d-f): transduced with the F5 TCR and GFP; g-i): 
transduced with F5 TCR and CD35-GFP; j-l): transduced with the F5 TCR and CD3^- 
GFP. This experiment was repeated 5 times with similar results.
87
CM
WT1
TCR
WT1 TCR+ 
CD36-GFP
WT1 TCR+ 
CD3?-GFP
WT1 TCR 
+ GFP
unstained anti-CD3 anti-Vp2.1 tetramer
Q1 0 2 0 1 0 2 01 0 2
, 2 1 Vl
Vi 9i.
'■4, 5"? * 1
$ $ *
0 4 0 4 0 4
10* 10* 10 10* , I...... I ..10* 10® 10 10* 10 10 10“ 10’
h
■ 01
I
' ca
50%
u
 *  a*
loi 02
x1.9
04‘n»i«r-rr-rnni -t i rum r*
01 02R1 x1.3
Vi
"2-1 ■ .-v^ T
~S1 04
10® 10® 10* 10*
%  .’
04
1?
n .n n r- r  n n m jp -  
10°  10
" " " I ,  r  
10S
n1Q1 02 %-101 02
56% %■
VsM :
x1
I ■ ■- art Vi &jSk-■
W$L IPr i , 04 * ‘ i ” 04 -rmi«|—mrrn*—m-tinn—r1
04
10® 10*
m m rj
10*
0
-01Vi
:
*1
10*  10* 10 10*
10*  10 10* 10*  10*  10 10*
01
■M-7‘f-' ..
02
x0.9
• . 04 i r I IT1IJ 1 1 .1.1.1 .
01“s-1
;Vi
V]
"h
Q2
x0.9
to1 ioJ ta* to5
GFP
Figure 4.10. Surface staining of 58ap' cells transduced with the WT1 TCR 
alone, with additional CD35-GFP, with additional CD3£-GFP or with GFP control 
vector.
After transduction, 58a-(3- cells were stained with anti-CD3, anti V(32.1 and tetramer. 
Figures in italics indicate events in Q4, figures in bold indicate the MFI of antibody or 
tetramer staining in Q2 as a multiple of the MFI in Q1 a-d): 58a-|3- cells transduced with 
the WT1 TCR; e-h): transduced with the WT1 TCR and CD35-GFP; i-l): transduced with 
WT1 TCR and CD3£-GFP; m-p): transduced with the WT1 TCR and GFP control. 
Representative results from 1 experiment are shown. This experiment was repeated 5 
times with similar results.
4.2.5 Increased TCR expression and tetramer binding in TCR/CD3£-GFP 
transduced 58a'p' cells correlates with increased IL2 production and increased 
sensitivity
Cytokine production by TCR+CD3£-GFP, TCR+CD36-GFP and TCR+GFP bulk 
transduced cells was compared using an IL2 ELISA. As previously, cells transduced 
with F5 TCR+CD36-GFP produced less IL2 than cells transduced with F5 TCR+GFP 
control (Figure 4.11). In contrast, cells transduced with F5 TCR+CD3£-GFP produced 
more IL2 than F5 TCR+GFP control cells at every peptide concentration. These 
results cannot be explained by differences in transduction efficiency, since the overall 
percentage of cells expressing V(311 did not vary greatly between the groups tested: 
61%, 57% and 57% for TCR+CD3£, TCR+CD35 and TCR+GFP, respectively (Fig 
4.11, b).
F5 TCR + CD3£-GFP cells stained with anti-V(311-PE antibody were sorted by FACS 
into two populations: V(311 only expressing cells and Vp11+GFP expressing cells. 
The phenotype of these cells is shown in Figure 4.12 a. IL2 production by sorted cells 
was compared using an ELISA. F5+CD3£-GFP transduced cells produced more IL2 
at each peptide concentration than F5 TCR only transduced cells (Fig 4.12, b). In 
addition, F5+CD3£-GFP transduced cells were more sensitive: they were able to 
recognise a ten fold lower concentration of peptide (1nM) than F5 TCR only 
transduced cells.
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Figure 4.11: 1L2 production by F5 TCR, F5 TCR+CD35-GFP and F5 TCR+CD3£-GFP transduced 58Q P- cells.
A: Bulk transduced F5 TCR, F5 TCR+CD35-GFP and F5 TCR+CD3£-GFP cells were stimulated for 24 hours with 
RMA-S cells loaded with relevant (NP366) or irrelevant (pSV9) peptides. Tenfold dilutions of relevant peptide were 
used (10pM-1nM). Supernatant was harvested as assessed for IL2 production by ELISA. Shown is the mean IL2 
concentration (pg/ml) +/- standard deviation of triplicate values. B: The phenotype of the cells used is shown.
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Figure 4.12: IL2 production by F5 TCR and F5 TCR+CD3£-GFP transduced, sorted 58a'p_ cells. 
A: phenotype of sorted (i) F5 TCR and (ii) F5 TCR+CD3£-GFP transduced 58ap' cells stained with anti-V(311 
antibody.
B: Sorted F5 TCR and F5 TCR+CD35-GFP transduced cells were stimulated for 24 hours with RMA-S cells loaded 
with relevant (NP366) or irrelevant (pSV9) peptides. Tenfold dilutions of relevant peptide were used (10pM-10pM). 
Supernatant was harvested as assessed for IL2 production by ELISA. Shown is the mean IL2 concentration (pg/ml) 
+/- standard deviation of triplicate values. Representative data is shown from 3 repeat experiments.
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4.3 Discussion
I have demonstrated that CD3 is a rate limiting step for the expression of both the 
introduced F5 and the WT1 TCR in 58°'p' cells. The addition of CD35-GFP resulted in 
a 3.7 fold increase in F5 TCR expression -  as measured by V(B11 staining - 
compared to a 1.2 fold increase in cells expressing TCR and the GFP control. Cells 
transduced with the WT1 TCR plus CD36-GFP showed a 3.8 fold increase in TCR 
expression, as measured by V(32.1 staining, compared to a 1.1 fold increase in TCR 
plus GFP control transduced cells. It is interesting to note that, after transduction with 
the WT1 TCR, 79% of cells stained with the anti-V(32.1 antibody, but only 0.2% of 
cells bound pWT126/HLA-A*0201 tetramer. In contrast, 4.5% of cells transduced with 
WT1 TCR and CD35-GFP bound the pWT126 tetramer, although the overall 
percentage of cells expressing V(32.1 was the same at 78%. The tetramer binding 
cells also express high levels of GFP, suggesting that the increased CD3 expression 
resulted in an increase in TCR density on these cells to a level which facilitated 
tetramer binding. Co-transduction of TCR genes with the modified CD3£-GFP vector 
resulted in a further increase in CD3 expression compared to co-transduction of TCR 
genes with the original CD35 construct, and subsequently up to a 6 fold increase in 
both F5 TCR surface expression and tetramer staining, and up to a 16 fold increase 
in WT1 TCR expression and tetramer staining.
My working hypothesis was that increased TCR density would correlate with 
increased sensitivity. Hofmann et al used transgenic mice expressing the same TCR, 
but with a five fold difference in expression levels to examine the effect of avidity on T 
cell function (212). They demonstrated that a five fold difference in TCR expression 
was sufficient to see a difference in sensitivity between the two groups: the TCR high 
splenocytes were able to lyse specific targets at a ten-fold lower peptide 
concentration. In addition, the high avidity T cells produced IL-2 and IFN-y in a 
peptide specific manner, whereas the low avidity T cells did not produce cytokine. 
This was in contrast to my data using the original CD35-GFP vector, where 58a‘p' 
cells expressing high levels of F5 TCR/CD35-GFP produced less IL-2 than 58a'p' 
cells transduced with the F5 TCR alone (Figure 4.5). This was not a result of the 
TCR/CD3 high cells being driven into apoptosis, as demonstrated by Figure 4.5.
It is well documented that TCR/CD3 complexes can be expressed on the surface of T 
cells in the presence of £ chain downregulation (213-215). The £ chain plays a crucial 
role in signal transduction upon ligation of the TCR, and it has been demonstrated 
that T cells which have downregulated CD3 £ chain expression are functionally
92
impaired. This phenomenon has been observed in T cells obtained from patients with 
chronic viral infections, cancers and autoimmune diseases (reviewed in 211). In 
conditions of chronic antigen exposure and chronic IFN-y production, myeloid 
suppressor cells are thought to contribute to downregulation of the £ chain through L 
arginine metabolism, as it has recently been shown that L arginine is required for 
expression of the £ chain (216;217). I hypothesized that TCR/CD35-GFP transduced 
cells were functionally impaired due to incorrect TCR/CD3 assembly, resulting from 
CD3 £ chains being translated at a disproportionately low frequency to that required 
for assembly of the fully functional TCR/CD3 complex. The new CD3£-GFP construct 
was designed to test this hypothesis, with the £ chain at the front of the cassette. As 
with the CD35-GFP construct, co-transduction with the CD3£-GFP construct and 
TCR also resulted in increased TCR expression in 58a‘p' cells. However, with the 
CD3£-GFP vector the increased TCR expression correlated with increased IL2 
production as well as increased sensitivity. 58a'p' cells expressing high levels of F5 
TCR/CD3 produced more IL2 at each peptide concentration than F5 TCR transduced 
cells, and also produced IL2 in response to a ten fold lower concentration of target 
antigen (Fig 4.12). This data is in keeping with Hoffman et a/’s findings that increased 
TCR density correlates with increased sensitivity, and suggests that the CD3£-GFP 
vector resulted in the production of the 4 CD3 genes at a more favourable ratio than 
with the CD35-GFP construct, such that the TCR/CD3 complexes which were 
expressed on the cell surface were also functional.
It would be interesting to look at the ratio of the different CD3 chains in 58a‘p' cells 
transduced with TCR or TCR plus CD35-GFP, to see if the CD3£ chain is 
proportionately under-represented in the latter group. This could be achieved via 
intracellular staining and a comparison of the ratios of the MFI of the different chains. 
However, there is currently no anti-murine CD3-£ antibody commercially available for 
intracellular staining. An alternative approach would be to use immunoprecipitation to 
assess the relative presence of the different £ chains, the working hypothesis being 
that the £ chain is under-expressed in the TCR/CD35-GFP high cells.
It was interesting to note that the increase in CD3 expression, and subsequently TCR 
expression, seen with the CD3£-GFP vector was consistently several orders of 
magnitude higher than that seen with the CD35-GFP vector. This is likely to be a 
result of the changes incorporated in the new CD3£-GFP construct design. Previous 
work in this laboratory has demonstrated that the pMP71 vector LTR used by the 
CD3£-GFP construct is more efficient than the murine stem cell virus LTR used by
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the CD35-GFP cassette. A stronger LTR would result in increased transcription of the 
cassette. In addition, codon optimisation of the CD3£-GFP construct would be 
expected to result in increased translation of the CD3 genes.
Another consistent finding was that the effect of co-transduction with CD3£-GFP on 
TCR expression was more marked with the WT1 TCR than the F5 TCR. The 
retroviral vectors for these TCRs use different LTRs, which may affect the level of a 
and (3 chains produced. The WT1 TCR was codon optimised, as this has been 
shown to increase the expression of exogenous TCRs in T cells (151). In addition, 
whereas the F5 TCR uses an IRES motif to link the a and (3 chains, the WT1 TCR 
vector uses a viral 2A sequence to link the a and (3 chains, which is likely to further 
increase the availability of WT1 TCR chains. It is likely that, as a result of these 
vector modifications, there is a more pronounced excess of WT1 a and (3 chains than 
F5 TCR chains. Therefore, the provision of large amounts of additional CD3£-GFP 
subsequently results in a higher level of WT1 TCR expression, as there are a greater 
number of WT1 TCR chains available to form TCR/CD3 complexes.
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Chapter 5: CD3 is rate limiting for the expression of a TCR introduced into 
primary T ceils by retroviral gene transfer 
5.1 Introduction
In the previous chapter it was established that the expression level of TCRs 
introduced into 58a‘p‘ cells by retroviral transduction can be increased several fold by 
co-transduction with CD3 molecules.
The situation with respect to the transduction of primary T cells is complicated by the 
presence of an endogenous TCR. Following TCR gene transfer, the introduced TCR 
will be in competition with the endogenous TCR for CD3 molecules (Figure 5.1). 
Introduced TCRs are often co-expressed with the endogenous TCR, which may 
reduce the density of introduced TCRs and hence affect their functional avidity. I 
hypothesized that the endogenous TCR and CD3 chains would be present in roughly 
equimolar quantities, and that there would not be a large excess of endogenous a 
and p TCR chains. Therefore, I would expect that the provision of additional CD3 
would not increase endogenous TCR expression on the cell surface. However, 
production of the a and p chains of the exogenous TCR is under the control of the 
retroviral promoter, so I would expect that there will be a relative excess of 
exogenous TCR chains. The working hypothesis was that provision of additional CD3 
molecules would therefore result in increased expression of the exogenous TCR. 
Furthermore, that increased TCR expression density would correlate with increased 
antigen specific cytokine production or sensitivity.
The aim of this chapter was to explore whether the co-transfer of TCR genes 
together with the genes encoding the yAe and £ chains of the CD3 complex can 
augment TCR expression. I have investigated the effect of additional CD3 on both 
endogenous TCR expression, as well as on the expression of an exogenous TCR 
introduced by retroviral gene transfer.
5.2 Results
5.2.1 Additional CD3 can increase endogenous TCR expression in primary T 
cells.
Activated C57BL/6 splenocytes were mock transduced, transduced with the CD36- 
GFP construct or the GFP control vector. Cells were stained with anti-CD3 and anti- 
TCR antibodies to monitor TCR expression levels. The MFI of anti-CD3 antibody
95
Figure 5.1: Competition between endogenous and exogenous TCRs for CD3 chains for surface expression
TCR a and (3 chains must form a complex with the and y CD3 chains in order for the TCR to be expressed on the 
cell surface. Following retroviral TCR gene transfer, there is competition between the endogenous TCR (in green) and 
the exogenous TCR (in blue) for CD3. A lack of available CD3 chains may reduce the density of expression of the 
exogenous TCR, which could reduce its functional avidity.
staining was 747 for untransduced splenocytes and 1140 for splenocytes transduced 
with the CD36-GFP vector: a 1.3 fold increase (Fig 5.2, e). The anti-TCR antibody 
MFI was 4423 for splenocytes which were not transduced by the CD35-GFP vector, 
and 6890 for those which were: a 1.56 fold increase (Figure 5.2, f). The increase in 
anti-TCR antibody MFI for GFP control transduced cells was from 3238 to 4321: a 
1.33 fold increase (Figure 5.2, i), corresponding with a 1.3 fold increase in anti-CD3 
antibody MFI (Fig 5.2, h). A small increase in TCR expression following transduction 
with the CD36-GFP construct compared to that seen with the GFP control was a 
consistent finding in repeat experiments.
The experiment was repeated using the new CD3£-GFP construct: activated 
C57BL/6 splenocytes were either mock transduced, transduced with the CD3£-GFP 
construct or the GFP control vector, and cells were stained with anti-CD3 and anti- 
TCR antibodies to monitor TCR expression levels. The MFI of CD3 antibody staining 
rose from 1095 in the absence of additional CD3 to 2726 in the presence of 
additional CD3 (Figure 5.3, e): a 2.75 fold increase. This was in contrast to GFP 
control transduced splenocytes, which demonstrated a 1.3 fold increase in anti-CD3 
MFI (from 976 to 1315) in the presence of GFP. The corresponding increases in anti- 
TCR antibody MFI were a 2.6 fold increase (from 13,222 to 34,522) and a 1.25 fold 
increase (from 12,429 to 15,513) for CD3£-GFP and GFP control transduced cells, 
respectively. This data was consistent in repeat experiments, and the increase in 
endogenous CD3 expression using the CD3£-GFP construct was always higher than 
that seen with the CD35-GFP construct. Hence, transduction of primary T cells with 
CD3£-GFP results in increased endogenous TCR expression, suggesting that there 
is an excess of endogenous TCR a and (3 chains. However, the increase was 
consistently far less marked than that seen in 58a p' cells.
5.2.2 CD3 is rate limiting for expression of both the F5 TCR and the WT1 TCR in 
primary T cells
I went on to explore the effect of co-transducing TCR and CD3 genes on exogenous 
TCR expression. Magnetic beads were used to deplete C56BL/6 splenocytes of V(3-
I I  expressing cells. Splenocytes were then activated and transduced with the F5 
TCR alone, with additional CD3£-GFP or with the GFP control construct. Cells were 
stained with anti-CD3, anti-Vp11 antibodies and tetramer to monitor expression of 
the exogenous TCR. Endogenous Vp-11 expression and tetramer staining were 
minimal in mock transduced, V(3-11 depleted T cells: 1.1% and 0.1% respectively. 
After transduction with the F5 TCR alone, V|3-11 expression and tetramer staining
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Figure 5.2: C57BL/6 splenocytes transduced with CD36-GFP or GFP control vector
After transduction, C57BL/6 splenocytes were stained with anti-CD3-PE antibody or an antibody directed 
against the TCR p chain constant region (anti-TCR-PE). Figures in italics indicate the transduction 
efficiency/percentage of cells in Q4. Figures in bold indicate the increase in antibody staining mean fluorescense 
intensity from Q1 to Q2. a-c: mock transduced; d-f: transduced with CD35-GFP; g-i: transduced with GFP control 
vector. Representative results from 1 of 5 repeat experiments are shown.
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Figure 5.3: C57BL/6 splenocytes transduced with CD3£-GFP or GFP control vector
After transduction, C57BL/6 splenocytes were stained with anti-CD3-PE antibody or an antibody directed 
against the TCR £ chain constant region (anti TCR). Figures in italics indicate the transduction efficiency/percentage of 
cells in Q4. Figures in bold indicate the increase in antibody staining mean fluorescense intensity from Q1 to Q2. a-c: 
mock transduced; d-f: transduced with CD3£-GFP; g-i: transduced with GFP control vector. Representative results from 
1 of 5 repeat experiments are shown.
rose to 15% and 1.3%, respectively (Fig 5.4; c,d). The MFI of Vp-11 expression 
increased from 3973 to 13945 in cells transduced with F5 TCR and F5 TCR + CD3£- 
GFP: a 3.5 fold increase, accompanied by a 9.5 fold increase in tetramer staining 
(from 1343 to 12820) (Fig 5.4; g,h). The corresponding increase in V(311 and 
tetramer MFI seen in control cells co-transduced with F5 and GFP was 1.1 fold (Fig 
5.4; k,l). The total percentage of cells which bound tetramer also increased in the 
presence of additional CD3: 3.7% versus 1.2% for TCR+CD3£ and TCR+GFP, 
respectively. The difference in TCR expression cannot be explained by differences in 
TCR viral titre or MOI, since a set volume of the same supernatant was used to 
transduce T cells. In addition, transducing cells with TCR as well as the GFP control 
excludes the possibility of these results being due to insufficient compensation prior 
to FACS analysis. Hence, cotransduction of F5 TCR and CD3£-GFP results in 
increased F5 TCR expression and tetramer staining in primary T cells
To ensure that this phenomenon was not limited to the F5 TCR, the experiment was 
repeated with the WT1 TCR. T cells were activated and transduced with the WT1 
TCR alone, with additional CD3£-GFP or with the GFP control vector. Cells were 
stained with anti-CD3, anti-human Vf32.1 antibodies and pWT126 tetramer to monitor 
expression of the exogenous TCR. Murine T cells did not bind the anti-human V(32.1 
antibody or WT1 tetramer. After transduction with the WT1 TCR alone, V|3-2.1 
expression rose to 18.3% (Fig 5.5; c), although only 0.2% of cells bound pWT126 
tetramer (Fig 5.5; d). The MFI of Vf32.1 expression increased from 1019 in cells 
transduced with WT1 TCR to 5013 in cells transduced with WT1 TCR+CD3£-GFP: a
4.9 fold increase (Fig 5.5; g). A corresponding 3.3 fold increase in tetramer staining 
(from 1260 to 4127) was also seen (Fig 5.5; h). A 1.1 fold increase in V(32.1 and 
tetramer MFI was seen in control cells co-transduced with WT1 TCR and GFP. The 
total percentage of cells which bound tetramer also increased in the presence of 
additional CD3: 2.5% versus 0.2% for TCR+CD3£ and TCR+GFP, respectively. As 
with the F5 TCR, increased tetramer binding was seen in cells expressing the highest 
levels of CD3£-GFP.
5.2.3 Primary T cells transduced with TCR plus CD3£-GFP display increased 
antigen specific cytokine production and increased sensitivity
IL2 and IFNy production by WT1 TCR+CD3£-GFP and WT1 TCR+GFP bulk 
transduced splenocytes was compared using an ELISA. The phenotype of the cells 
used is shown in Figure 5.5. Cells transduced with WT1 TCR+CD3£-GFP produced
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Figure 5.4: Surface staining of Vp11 depleted C57BL/6 splenocytes transduced with the F5 TCR alone, F5 
TCR plus CD3£-GFP or F5 TCR plus GFP control. C57BL/6 splenocytes were V(311 depleted prior to activation. 
Following transduction, cells were stained with anti-CD8a-APC and anti-CD3-PE, anti Vp11-PE or tetramer-PE to 
assess F5 TCR expression. Shown are gated CD8+ cells, a-d): transduced with F5 TCR; e-h): transduced with F5 
TCR + CD3£-GFP; i-l): transduced with F5 TCR and GFP control. Figures in bold indicate the increase in mean 
fluorescence intensity between Q1 and Q2. Representative data from 1 of 5 repeat experiments is shown.
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Figure 5.5: Surface staining of C56BL/6 splenocytes transduced with the WT1 TCR alone, WT1 TCR plus CD3£-GFP
or WT1 TCR plus GFP control. Following transduction, cells were stained with anti-CD8a-APC and anti-CD3-PE, anti V(32.1- 
PE or WT1 tetramer-PE to assess WT1 TCR expression. Shown are gated CD8+ cells. Figures in bold indicate the increase 
in mean fluorescence intensity between Q1 and Q2. a-d): transduced with WT1 TCR; e-h): transduced with WT1 TCR + 
CD3£-GFP; i-l): transduced with WT1 TCR and GFP control. Representative data from 1 of 5 repeat experiments is shown.
more IFNy than WT1 TCR+GFP control cells at each peptide concentration (Fig 5.6). 
These results cannot be explained by differences in transduction efficiency, since the 
overall percentage of cells expressing V(32.1 was similar in the two groups: 19.5% 
and 18% for WT1 TCR+CD3£ and WT1 TCR+GFP, respectively. Similarly, cells 
transduced with WT1 TCR+CD3£-GFP produced more IL2 than WT1 TCR+GFP 
control cells at each peptide concentration (Fig 5.7).
ELISAs consistently demonstrated that TCR+CD3£-GFP transduced cells produced 
more cytokine than TCR+GFP control cells at each peptide concentration, but failed 
to clearly reveal a difference in sensitivity between the two groups. I hypothesized 
that this was due having used bulk transduced cells in the assays, and that 
comparing the TCR/CD3£-GFP high cells to the TCR/GFP cells would demonstrate a 
difference. I therefore went on to perform intracellular cytokine staining on WT1 
TCR+CD3£-GFP and WT1 TCR+GFP transduced cells. Due to TCR down-regulation 
following antigen specific stimulation, I was unable to gate on V(32.1 expressing cells. 
However, I have previously shown that GFP correlates with TCR expression in CD3£- 
GFP transduced cells, so I gated on FITC high cells and compared IFNy production 
by the GFP high cells in WT1 TCR+CD3^-GFP and WT1 TCR+GFP transduced 
cells. The gating strategy is shown in Figure 5.8 (a). Flow cytometric analysis of the 
two groups of cells on the day prior to setting up the stimulation revealed that V(32.1 
expression was 97% and 53% in the GFP high populations of TCR+CD3£-GFP and 
TCR+GFP cells, respectively. The relative IFNy production was calculated according 
to the equation x = y/z x100, where x = relative IFNy production, y = actual IFNy 
production and z = the percentage of cells expressing V(32.1. (For example, if 10% of 
TCR+GFP control cells produce IFNy, then relative IFNy production = 10/53 x100 = 
18.9%.) In keeping with the ELISA data, both groups of cells produced IFNy in an 
antigen specific manner, and WT1 TCR+CD3£-GFP transduced cells produced more 
IFNy than WT1 TCR+GFP control transduced cells at each peptide concentration. 
However, gating on the CD8+ GFP high population demonstrated that WT1 
TCR+CD3£-GFP transduced cells also showed increased sensitivity, and were able 
to recognise a ten fold lower peptide concentration of pWT126 (1nM) than CD8+, 
GFP high, WT1 TCR+GFP control transduced cells (10nM) (Fig 5.8; b).
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Figure 5.6: IFNy production by WT1 TCR + CD3£-GFP and WT1 TCR + GFP control 
transduced cells. WT1 TCR + CD3£-GFP and WT1 TCR + GFP control transduced 
cells were stimulated for 24 hours with T2 cells loaded with relevant (pWT126) or 
irrelevant (pMelanA) peptides. Tenfold dilutions of relevant peptide were used (10pM- 
1nM). Supernatant was harvested and assessed for IFNy production by ELISA. Shown is 
the mean IFNy concentration (pg/ml) +/- standard deviation of triplicate values. 
Representative data is shown from 1 of 3 repeat experiments
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Figure 5.7: IL2 production by WT1 TCR + CD3^-GFP and WT1 TCR + GFP control 
transduced cells. WT1 TCR + CD3£-GFP and WT1 TCR + GFP control transduced 
cells were stimulated for 24 hours with T2 cells loaded with relevant (pWT126) or 
irrelevant (pMelanA) peptides. Tenfold dilutions of relevant peptide were used (10pM- 
1nM). Supernatant was harvested and assessed for IL2 production by ELISA. Shown is 
the mean IL2 concentration (pg/ml) +/- standard deviation of triplicate values. 
Representative data is shown from 1 experiment (n=3)
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Figure 5.8: IFNy production by WT1 TCR/CD35-GFP and WT1 TCR/GFP transduced 
cells
Intracellular IFN- detection was performed on 1 x 106 T cells stimulated with 5 x 105 T2 
cells loaded with either relevant (pWT126) or irrelevant (pMelanA) peptide. Tenfold 
dilutions of relevant peptide were used (1pM-100pM). After 2 hours, Brefeldin A was 
added to block cytokine secretion, and after a further 12 hours staining was performed. 
Cells were stained with anti-CD8-APC antibody, then fixed, permeabilized and stained 
with IFN-y PE. A: of the CD8 positive lymphocytes, the GFP high population was 
selected (P1) for analysis of IFNy production. B: IFNy production by P1 in WT1+CD3£- 
GFP and WT1+GFP transduced cells. Due to differences in V02.1 expression in the two 
groups analysed, IFNy production was calculated according to the equation x = y/z x100, 
where x = relative IFNy production, y = actual IFNy production and z = %V(32.1 
expression. Representative results from 1 of 3 repeat experiments are shown.
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Gating on GFP negative (P1) and GFP high (P2) cells within the WT1 TCR+CD3£- 
GFP transduced cell population also demonstrates a difference in sensitivity between 
P1 and P2 (Figure 5.9; b): GFP high cells are able to recognise a ten fold lower 
peptide concentration of pWT126 (1nM) than GFP negative WT1 TCR+CD3£-GFP 
transduced cells (10nM). Together, this data demonstrates that increased density of 
WT1 TCR expression secondary to cotransduction with CD3£-GFP results in not only 
increased cytokine production, but also an increase in sensitivity.
5.2.4 Endogenous Va2 expression is reduced in C57BL/6 splenocytes 
expressing high levels of WT1 TCR
A potential concern regarding this strategy to increase exogenous TCR expression is 
that co-transduction of CD3 genes could result in increased expression of both the 
endogenous and the exogenous TCRs, and that this might result in increased 
expression of “mis-paired” TCRs comprised of an endogenous a and exogenous (3 
chain. To begin to address this question, I investigated the effect of transducing 
primary T cells with WT1 TCR (which uses the Va1.5 chain) and CD3£-GFP on 
endogenous Va2 expression. Va2 is expressed in the endogenous repertoire at a 
frequency of approximately 10% (Figure 5.10; c,f). I compared Va2 expression in 
cells which had not been transduced with the WT1 TCR, with expression on cells 
which had been transduced with the WT1 TCR only or on cells which expressed very 
high levels of WT1 TCR and CD3. The Va2 expression in these three groups was 
10.4%, 6.4% and 1.2%, respectively (Figure 5.11; c-e). In contrast, Va2 expression in 
WT1 TCR and WT1 TCR plus GFP control expressing cells was almost unchanged 
at 5.8% and 5.7%, respectively (Fig 5.11; g,h). This data demonstrates that cells 
which expressed high levels of the WT1 TCR and CD3 expressed very low levels of 
Va2, which does not support the hypothesis that there is increased endogenous TCR 
expression and subsequent mispairing in these cells.
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Figure 5.9: IFNy production by GFP high and GFP negative WT1 TCR/CD3£-GFP 
transduced T cells
Intracellular IFNy detection was performed using 1 x 106 T cells stimulated with 5 x 105 
T2 cells loaded with either relevant (pWT126) or irrelevant (pMelanA) peptide. Tenfold 
dilutions of relevant peptide were used (1pM-100pM). After 2 hours, Brefeldin A was 
added to block cytokine secretion, and after a further 12 hours staining was performed. 
Cells were stained with anti-CD8-APC antibody, then fixed, permeabilized and stained 
with IFN- PE. A: of the CD8 positive lymphocytes, a GFP negative population (P1) and a 
a GFP high population (P2) were selected for analysis of IFNy production. B: IFNy 
production by WT1+CD3£-GFP transduced cells in P1 and P2. Due to differences in 
V02.1 expression in the two groups analysed, IFNy production was calculated according 
to the equation x = y/z x100, where x = relative IFNy production, y = actual IFNy 
production and z = %V|32.1 expression. Representative results from 1 of 3 repeat 
experiments are shown.
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Figure 5.10: Endogenous Va2 expression is reduced in WT1 TCR expressing C57BL/6 splenocytes.
Splenocytes transduced with WT1 TCR+ CD3^-GFP or WT1 TCR+ GFP control were stained with V(32.1-PE 
and anti-Va2-APC antibodies. The frequency of Va2 chain expression was assessed in P1: cells which did not 
express the WT1 TCR (c and f); P2: cells which were WT1 TCR positive and GFP negative (d and g) and P3: 
the top 0.5% of GFP expressing cells, which also expressed the WT1TCR (e and h).
5.3 Discussion
The data presented demonstrates that increasing the availability of CD3 results in 
increased TCR expression in primary T cells.
Endogenous TCR expression showed only a modest 1.5 fold increase in the 
presence of additional CD35-GFP. Of note, the TCR dull population was seen to 
disappear in the presence of additional CD3, whereas the TCR high population is 
unchanged. One explanation for this is that the TCR dull population represents T 
cells which express ‘weak’ TCRs, where the a and p chains do not fold and associate 
with CD3 complexes as efficiently. Hence, for T cells expressing ‘weak’ TCRs, the 
provision of additional CD3 is beneficial and results in increased TCR expression to a 
level similar to that seen with ‘stronger’ TCRs which fold and associate with CD3 
molecules more efficiently, and are naturally expressed at a higher density.
In contrast, both CD3 expression and endogenous TCR expression showed up to a
2.5 fold increase following transduction with CD3£-GFP. The level of CD3/GFP 
expression from this vector was consistently much higher than that seen with the 
CD35-GFP vector. This is likely to be a result of the combined effects of changing to 
the pMP71 LTR and also codon optimising the CD3£-GFP vector. In T cells 
transduced with the CD3£-GFP vector, the TCR dull population again disappears, as 
seen with the CD35-GFP vector. However, with further increases in CD3 provision, 
there is a proportional increase in TCR expression. This suggests that there is an 
excess of TCR a and (3 chains in primary T cells, and that the availability of CD3 
molecules is a rate limiting step for the formation of TCR/CD3 complexes and for 
surface expression of endogenous TCRs.
My working hypothesis was that additional CD3 would have a more profound effect 
on the expression of an exogenous TCR introduced by retroviral gene transfer. This 
was on the basis that the exogenous a and p chains are expressed under the control 
of a viral promoter, and were therefore likely to be present in excess. Indeed, in the 
presence of additional CD3, both F5 and WT1 TCR expression consistently showed 
over a five fold increase in Vp antibody MFI compared to T cells transduced with the 
TCR alone (Fig 5.4 & 5.5). The most likely explanation for the data is that 
endogenous and exogenous TCRs are in competition for CD3 for surface expression, 
and that increasing the availability of CD3 molecules allows a greater number of 
exogenous TCR chains to form TCR/CD3 complexes and be expressed on the cell 
surface. Figure 5.5 shows a 2.5 fold increase in CD3 expression in cells transduced
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with CD3£-GFP. However, the increase in exogenous V(B2.1 expression is greater at
4.9 fold. This is indirect evidence that the additional CD3 is exerting a proportionately 
greater effect on exogenous WT1 TCR expression compared to endogenous TCR 
expression.
It was interesting to note that cells transduced with either the WT1 TCR alone or the 
WT1 TCR + GFP control, which could be stained with the V(32.1 antibody, did not 
stain with the WT1 tetramer. One explanation for this could be that the introduced 
V|32.1 chain is mispairing with the endogenous a chain, and that the mixed dimer 
does not bind tetramer. However, it may also relate to the tetramer used, since cells 
transduced with the WT1 TCR or TCR + GFP consistently produced IL2 and IFNy in 
an antigen specific manner, suggesting that there was correct pairing of the 
introduced TCR genes. Tetramer binding does not always correlate with function: T 
cells which do not bind tetramer, but are still functional, have been described in the 
literature, as have cells which bind tetramer, but which do not secrete cytokines 
(186;218). Furthermore, it was observed with both the F5 and the WT1 TCRs that 
tetramer binding also increased in cells co-transduced with TCR and CD3£-GFP, 
which expressed higher levels of TCR, despite the Vp expression being similar to 
that seen in TCR only or TCR + GFP transduced cells. This is likely to relate to there 
being a minimum density of TCR expression which is required in order for tetramer to 
stably bind. In the presence of additional CD3, TCR density may increase beyond the 
threshold required for tetramer binding.
Nonetheless, with regard to cytokine production, there was consistently a greater 
response seen in the TCR+CD3£-GFP cells compared to the TCR+GFP control cells 
expressing a similar level of Vp2.1. However, it was difficult to detect a difference in 
avidity using ELISA on bulk transduced cells because the proportion of TCR/CD3 
bright cells is small, and any effect may be diluted by cells which were only 
transduced with the TCR. However, intracellular cytokine staining allowed me to gate 
on the GFP bright cells, and compare IFNy production by GFP bright CD8+ cells in 
the TCR+CD3£-GFP and TCR+GFP control populations, thus excluding from the 
analysis cells which expressed the TCR, but not additional CD3. This technique 
enabled me to demonstrate that increased density of TCR expression correlated with 
an increase in antigen specific IFNy production as well as increased sensitivity: WT1 
TCR+CD3£-GFP transduced cells not only produced more IFNy at each peptide 
concentration, but were also able to recognise a ten fold lower concentration of 
pWT126 than WT1 TCR+GFP transduced cells (Fig 5.8). Analysis of the MFI of IFNy
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staining in WT1 TCR+ CD3£-GFP and WT1 TCR+GFP transduced cells was similar 
(4149 and 4420, respectively). This suggests that IFNy production by individual cells 
following TCR triggering is not different. Rather, that the increased IFNy production is 
a result of a greater proportion of the WT1 TCR+CD3£-GFP cells responding. Given 
that this is not due to differences in overall V(32.1 expression between the two 
groups, this suggest that increased density of V(32.1 expression in the CD3 high cells 
reaches a threshold above which they can respond to antigen.
My data is again in keeping with the work by Hofmann et al, who demonstrated that a 
five fold difference in TCR expression level was sufficient to see a difference in 
sensitivity; TCR high splenocytes were able to produce cytokine and lyse specific 
targets at a ten-fold lower peptide concentration (212). This work was somewhat at 
odds with previous data from Mathis’ group, who had used a tetracyline based 
control system to generate transgenic mice expressing different levels of the same 
TCR. They showed that a 20 fold reduction in TCR expression, with T cells 
expressing as few as 1000 TCRs per CD8 T cell, could still result in cytokine 
production in response to saturating concentrations of antigen, although they did not 
address the issue of sensitivity (219). However, both of these models employ 
transgenic mice which only express a single TCR, so the data does not mimic the 
situation in TCR transduced primary T cells, where there is competition between the 
endogenous and exogenous TCRs for surface expression. The data presented in this 
chapter demonstrates that increasing the density of exogenous TCR expression, by 
co-transduction with CD3, can increase the T cell avidity and improve antigen 
specific function. This may be a strategy by which the avidity of a lower affinity TCR 
can be improved. There is now evidence that exogenous TCR expression following 
gene transfer can vary widely, depending on the characteristics - and the relative 
strength - of both the endogenous and exogenous TCR (220;221). It may be that 
‘stronger’ TCRs, which fold and form complexes with CD3 molecules more efficiently 
than endogenous TCRs, will benefit most from the provision of additional CD3. In 
cases where the exogenous TCR naturally out-competes the endogenous TCR for 
CD3, the increased provision of CD3 molecules may further increase exogenous 
TCR density to a level which results in increased sensitivity.
A potential safety issue with retroviral TCR gene transfer is that it has been 
demonstrated that exogenous TCRs can mispair with endogenous TCR chains (150). 
Mispaired TCRs, comprised of a and (3 chains from each of the endogenous and 
exogenous TCRs, have not undergone negative selection in the thymus and
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therefore have the potential to be autoreactive. Even if mispaired TCRs are not 
autoreactive, any mispairing may reduce the expression density and hence the 
efficacy of the desired TCR. A number of strategies have recently been employed to 
address this issue. TCRs have been engineered to include an additional cysteine 
residue in the constant regions of the a and (3 chains, resulting in the formation of a 
second disulphide bond between them. T cells transduced with cysteine-modified 
receptors showed increased tetramer binding, secreted more cytokine and showed 
increased antigen specific lysis when co-cultured with specific tumour cell lines, 
compared with T cells expressing wild type TCR (150;222). Hybrid TCRs have also 
been designed to incorporate murine constant regions and human variable regions. 
These hybrid TCRs show reduced mispairing with fully human TCRs when 
introduced into human T cells, combined with superior cell surface expression and 
biological activity (150;223). However, there is a possibility that a human host will 
mount an immune response against the murine component of such a TCR. In the 
same way as murine monoclonal antibodies have become increasingly humanised 
for clinical use, it is likely that murinization of the TCR constant region will be 
minimized to reduce its immunogenicity, if this strategy is to be used in a clinical 
setting.
An important question to address will be whether co-transduction of TCR and CD3 
genes also results in increased expression of mispaired TCRs. The data presented 
here suggests that that co transfer of TCR and CD3 genes resulted in cells which 
expressed very high levels of the introduced TCR, but substantially reduced levels of 
endogenous Va2 (Fig 5.10). Of note, the data presented in this chapter only 
assesses the effect of WT1 TCR expression on endogenous Va2 expression, and it 
would be important to confirm this observation by repeating the experiment using 
antibodies against a range of different endogenous Va and V(3 chains.
Recent data has shown that ‘strong’ TCRs are expressed at high levels following 
retroviral gene transfer, whereas ‘weak’ TCRs compete poorly with the endogenous 
TCR repertoire for CD3 molecules and are poorly expressed (220;224). Strategies 
such as murinisation of constant domains and cysteine modification of TCR chains 
also serve to increase the ‘strength’ of TCR expression (150,221 ;225). Since it is 
likely that co-transduction with CD3 will be most effective at increasing the 
expression of strong TCRs, there is the potential for these strategies to be used in 
combination. If cells expressing high levels of the exogenous TCR/CD3 consistently 
demonstrated decreased expression of endogenous TCR chains, these cells could
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be sorted by FACS to produce a population of cells with both a low risk of mispairing 
which also express a high avidity exogenous TCR. Using these cells for adoptive 
transfer would reduce the risk of autoimmunity resulting from mispaired TCR chains. 
Furthermore, I would hypothesize that the adoptive transfer of a smaller number of 
higher avidity T cells, demonstrating increased sensitivity in vitro, would be required 
to confer tumour protection in vivo. It would be interesting to compare the ability of 
the TCR/CD3£-GFP high and TCR/GFP high cells to persist following adoptive 
transfer, as well as their ability to respond to antigen and confer tumour protection in 
vivo.
6. General Discussion
There are a number of potential barriers to successful cancer immunotherapy. The 
majority of targets identified to date are over-expressed self antigens, such as WT1. 
This raises the issue of immunological tolerance, as one would expect CTL which 
recognise self antigens with high avidity to be deleted in the thymus. However, 
central tolerance is incomplete, and it is clear that autologous responses against 
tumour antigens such as WT1 can be detected in patients with cancer 
(67; 116; 157; 160; 184). Nonetheless, the impact of autologous responses on the 
natural history of tumour development is unknown. It may be that autologous immune 
responses against tumour antigens are evidence of immune surveillance. However, 
an alternative explanation is that they are just evidence of the presence of the 
tumour, since recent data in a sporadic murine tumour model demonstrated that the 
appearance of tumour specific antibody and CD8 T cell responses correlated with the 
development of tumours, but not with the emergence of tumour escape variants (12).
It has been demonstrated in murine models and in clinical trials that autologous 
responses against WT1 can be boosted by vaccination. Different groups have shown 
that vaccination of mice with WT1 peptides can generate WT1 specific T cells 
capable of lysing target cells loaded with their cognate peptide. However, whereas 
Oka et al demonstrated that these T cells could protect mice against subsequent 
challenge with WT1 expressing tumour cells, this was inconsistent with work by 
Ramirez et al, who subsequently showed that WT1 CTL generated by vaccination did 
not kill tumour cells in vitro or confer tumour protection in vivo (93; 117). What is not 
clear is whether this discrepancy is due to vaccination having induced WT1 CTL of 
different avidities in the two models, or whether it is a result of having used different 
WT1 expressing tumours as targets. Both Phase I WT1 vaccination trials in humans 
have demonstrated that vaccination resulted in an increased frequency of WT1 CTL 
in a proportion of patients with WT1 expressing malignancies. Furthermore, the 
presence of WT1 CTL was associated with clinical responses including a reduction in 
leukemic blast cells, tumour markers, WT1 mRNA copy number or tumour size (116) 
(188). However, these results need to be interpreted with caution owing to the small 
number of patients enrolled in these trials, and it should be noted that only 3 out of 5 
patients with solid tumours would be considered to have shown a partial response to 
treatment according to the standard RECIST criteria used in oncological clinical trials 
(226). In the absence of data from a large, randomised, Phase III clinical trial, a 
question mark still remains over whether or not WT1 CTL generated from the
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autologous repertoire of cancer patients will be of sufficient avidity to kill tumour cells 
in vivo. Tumour vaccination strategies in general have not been met with the large 
scale clinical success that was initially anticipated. Most reports are from small phase 
I trials and results are varied, with some studies demonstrating a correlation between 
clinical responses and vaccine induced immune responses, and others showing 
immune responses in the absence of clinical responses, and vice versa (227-229). 
The vast majority of clinical work in the vaccination field has been performed in 
melanoma, where a recent review incorporating data from 422 patients with 
metastatic melanoma who underwent peptide vaccination demonstrated an objective 
clinical response rate of only 2.6% when RECIST criteria were applied (89).
At present there is a lack of compelling evidence that vaccination in isolation will be 
enough to cause regression of solid tumours in the majority of patients. Concerns 
remain over whether tumour antigen specific T cells from the autologous repertoire 
will be of sufficient avidity to mount an effective anti tumour response in vivo. Recent 
data in a murine transgenic model of T cell tolerance demonstrated that although T 
cells specific for the murine double minute tumour antigen escaped central tolerance 
and were present in the periphery, their ability to proliferate and express effector 
molecules in response to antigen stimulation was impaired. These defects could be 
restored if cells were stimulated in the presence of IL2, and to a lesser extent IL15 or 
IL21. However, even after tolerance was broken with IL2, the ‘rescued’ T cells were 
of lower avidity than non tolerant control T cells expressing the same TCR (230). 
Thus, even if tolerance can be broken and autologous WT1 specific T cell responses 
can be boosted by vaccination, whether these cells will be of sufficient avidity to lyse 
tumour cells in vivo is not clear at present, but appears doubtful.
TCR gene therapy is a strategy by which autologous T cells which recognise tumour 
associated antigens with high avidity can be generated. This technique enables the 
production of large numbers of autologous, antigen specific T cells, with the added 
advantage that the introduced TCR specificity can be directed against poorly 
immunogenic targets. There are several methods by which high avidity CTL specific 
for TAAs can be generated. Immunisation of HLA transgenic mice, the allo-restricted 
approach, in vitro mutagenesis of TCRs and in vitro selection using phage display 
can be used to generate TCRs with increased peptide/MHC binding affinity 
(133; 164;231 -233) (133;234-236). TCRs can be isolated and functionally tested 
before being retrovirally transferred into patients’ T cells, where the redirected T cells 
demonstrate the same functional avidity as the original parent T cell from which the
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TCR genes are cloned (133;237). Transduced T cells have been shown to contribute 
to tumour clearance in murine models (202) (200) and the first clinical trial of TCR 
gene transfer was recently reported. Retroviral gene transfer was used to transduce 
peripheral blood lymphocytes, taken from patients with melanoma, with the genes 
encoding the a and (3 chains of a TCR with specificity for a MART 1 peptide 
presented by HLA-A*0201 (238). The 17 patients in the gene transfer study were 
lymphodepleted prior to receiving autologous T cells transduced with the MART-1 
TCR. The engineered T cells persisted in 15 patients, and the two patients with the 
highest levels of circulating anti melanoma T cells showed objective regression of 
metastatic lesions and remained in remission 18 months after treatment (137). The 
results of this study prove that retroviral TCR gene transfer can be used to confer anti 
tumour specificity upon a large number of T cells, and that these T cells can engraft 
in patients and persist at high levels longterm.
While TCR gene transfer holds promise, there may yet be obstacles to overcome 
with respect to either the safety or the efficacy of this strategy. Firstly, mispairing of 
endogenous and exogenous TCR chains may result in ‘off target’ toxicity. Secondly, 
high avidity CTL may cause ‘on target’ toxicity by attacking normal tissues which 
express low levels of the target antigen. Thirdly, adoptively transferred T cells may be 
subject to tolerance mechanism which render them unresponsive in vivo. I will 
address each of these in turn.
Although there is no evidence of off target toxicity in murine models to date, it has 
been demonstrated that exogenous TCR are able to mispair with endogenous TCR 
chains, resulting in the expression of TCRs which have not undergone thymic 
education, with unpredictable specificities, which have the potential to be 
autoreactive. As described in chapter 5, several strategies have been employed to 
reduce mispairing and increase expression of the desired TCR. These include 
murinization of TCR constant domains and cysteine modified TCR chains, both of 
which have been shown to result in increased TCR expression and tetramer binding 
compared with wild type TCRs (150; 222; 225). Furthermore, the strategy described 
in Chapter 5 of this thesis may be a mechanism by which cells expressing only high 
levels of the introduced TCR can be generated. Research is ongoing into alternative 
means by which the risk of mispairing may be reduced. It has recently been shown 
that TCR a and (3 chains which have each been linked to a CD3£ chain did not 
mispair with endogenous TCR chains in a Jurkat T cell model (239). Since y5 TCR 
chains cannot mispair with a(3 TCR chains, transferring a|3 TCR chains into y6 T cells
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should not result in any mispairing, and has previously been shown to result in the 
expression of exogenous ap TCR which produce cytokine and lyse target cells in an 
antigen specific manner (240). Transduction of viral specific T cells is a strategy by 
which the potential number of mixed dimers can be reduced, since anti viral 
responses consist of T cells with a restricted TCR repertoire (201). An alternative 
approach would be to transduce haematopoetic stem cells (HSC) with TCR genes. In 
vitro generation of mature, antigen specific T cells by TCR gene transfer into thymus 
or cord derived HSC has recently been reported (241;242). Allelic exclusion of the 
endogenous TCR p chain meant that mixed dimer formation was reduced, but not 
entirely avoided due to some endogenous a chain expression. Furthermore, while 
the risk of transformation of mature T cells is low, the risk in HSC may be higher, 
making this a less appealing strategy (243). In a clinical trial of X linked severe 
combined immunodeficiency disease, 4 children treated with HSC retrovirally 
transduced with the common y chain developed T lymphoproliferative disorders. This 
was later found to be secondary to retroviral insertion into the LMO-2 oncogene 
intron on chromosome 11, with subsequent upregulation (244-246). Although there is 
no evidence to date of transformation of mature T cells with retroviral vectors, the use 
of lentiviral vectors is also being investigated, since it has been shown that lentiviral 
vectors insert near promoters at a lower frequency.
While there is a concern that low avidity, TAA specific CTL from the autologous 
repertoire may not be efficacious, high avidity, self reactive CTL may pose the 
opposite problem. The majority of targets for tumour immunotherapy are over­
expressed self proteins, so there is a risk that targeting TAA may result in 
autoimmune damage. In murine models and in clinical trials it has been 
demonstrated that the successful induction of CTL responses against melanoma 
TAAs (such as melan A or gp100) has been associated with the development of 
vitiligo (247-250). T cell therapies targeting TAAs with a more ubiquitous distribution 
have not been studied in the same detail as yet, although it has been shown that high 
avidity p53 specific CTLs (generated in p53_/‘ transgenic mice) can provide tumour 
protection without causing autoimmune damage in mice (251). A moderately high 
affinity TCR was used in the TCR gene therapy trial, and work is now ongoing by the 
same group to test a higher avidity TCR. It remains to be seen whether any morbidity 
resulting from autoimmune disease outweighs the associated anti tumour benefit. A 
balance needs to be struck between TAA specific CTL which are of high enough 
avidity to mediate tumour killing, but which do not cause significant autoimmune 
damage to healthy tissue. It is likely that a large discrepancy between the expression
118
level of the target antigen on tumour tissue compared to that on normal tissue will be 
an important factor in this regard, as will the pattern of distribution of the TAA in 
normal tissue. A validated definition of WT1 over-expression, which predicts tumour 
susceptibility to adoptively transferred TCR transduced cells, may be required.
An alternative consequence of TCR gene transfer may be that T cells expressing 
high avidity TCRs will be more susceptible to tolerance mechanisms in vivo following 
adoptive transfer. At present it is unclear why only 2 patients in the TCR gene 
therapy trial responded clinically, when 15 patients demonstrated persistence of the 
engineered T cells, which made up at least 10% of their circulating T cells for more 
than two months after treatment. One explanation is that the adoptively transferred T 
cells were rendered unresponsive in vivo. There may therefore be a role for 
combining adoptive T cell transfer with mechanisms to break tolerance. The 
conditions required for induction of tolerance are not well defined, but data from 
animal models suggests that the presentation of antigen in the absence of 
inflammatory stimuli results in tolerance (252). There are a number of mechanisms of 
T cell tolerance, including down regulation of the TCR or other molecules such as 
CD8, and interference with the IL2 signalling pathway (253-256). Various 
mechanisms by which tolerance can be reversed have been identified, most of which 
involve manipulation of T cell co-stimulatory pathways. For example, exogenous IL2, 
signalling through 0X40 (CD134), CD40 ligation and anti CTLA-4 antibodies have all 
been shown to break tolerance in murine models, and the data presented in Chapter 
3 is the first demonstration of tolerance reversal with IL15 in human T cells 
(159;230;257-259). However, in addition to naturally occurring tolerance 
mechanisms, there are additional factors to consider in the presence of solid 
tumours. It has been demonstrated both in humans and in murine tumour models 
that T cells derived from, tumour bearing hosts are dysfunctional (130, 156). As 
described in Chapter 4, chronic inflammation and persistent IFNy production may 
result in the generation of myeloid suppressor cells, which contribute towards T cell 
dysfunction via downregulation of the CD3£ chain. In addition, tumours may actively 
secrete immunosuppressive factors such as TGF(3 or IL10. The full range of 
mechanisms by which tumours induce tolerance are still undefined, and the roles 
played by regulatory T cells, myeloid suppressor cells and other immunosuppressive 
factors present in the tumour microenvironment continue to emerge.
Tolerance induction is only one possible explanation as to why only 2 out of 15 
patients in the trial responded clinically to TCR gene therapy. It may be that the level
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of expression of the target antigen on tumours varied between patients, or that the 
tumours which did not respond had downregulated MHC Class 1 expression or 
become otherwise immunoresistant. The factors that allow certain patients to 
respond well to immunotherapy need to be more fully understood, in order that 
treatments can be improved and also targeted to those patients most likely to benefit. 
Given the ability of tumours to mutate and react to their environment, there is also a 
concern that therapy directed at a single target, such as WT1, may apply selective 
pressure to the tumour and lead to the emergence of escape variants. Selecting a 
target which is required for maintenance of the oncogenic phenotype will hopefully 
mean that down-regulation of the target will limit the cell’s malignant potential. 
Another option is to simultaneously attack more than one target, via more than one 
mechanism. Combination therapy has previously been shown to be effective in both 
antiretroviral therapy as well as chemotherapy, and trials which combine standard 
chemotherapy with immunotherapy, or immunotherapy with tyrosine kinase inhibitors, 
are currently underway. Although B cell cancer immunotherapy has seen greater 
clinical acclaim in recent years through the success of monoclonal antibody therapy, 
TCR gene transfer has now entered Phase I clinical trials. Further work is needed to 
identify the patients most likely to benefit from such a strategy, and randomised trial 
data is still some way off, but the field of T cell cancer immunotherapy is currently 
one to be watched closely.
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Appendix 1:
CD3 ze#a-F2A-CD3 eps#/on-T2A-CD3 delta -E2A-CD3 gamma nucleotide 
sequence
5’ Not 1 and 3’ Sail restriction sites are underlined 
2A sequences are in BOLD CAPS
Gcggccgcatgaagtggaaagtgtctgttctcgcctgcatcctccacgtgcggttcccaggagcagaggcacagag
ctttggtctgctggatcccaaactctgctacttgctagatggaatcctcttcatctacggagtcatcatcacagccctgtacc
tgagagcaaaattcagcaggagtgcagagactgctgccaacctgcaggaccccaaccagctctacaatgagctca
atctagggcgaagagaggaatatgacgtcttggagaagaagcgggctcgggatccagagatgggaggcaaacag
cagaggaggaggaacccccaggaaggcgtatacaatgcactgcagaaagacaagatggcagaagcctacagtg
agatcggcacaaaaggcgagaggcggagaggcaaggggcacgatggcctttaccagggtctcagcactgccac
caaggacacctgtgatgccctgcatatgcagaccctggcccctcgcGTGAAGCAGACTTTGAATTTTG
ACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCatgcggtggaa
cactttctggggcatcctgtgcctcagcctcctagctgttggcacttgccaggacgatgccgagaacattgaatacaaa
gtctccatctcaggaaccagtgtagagttgacgtgccctctagacagtgacgagaacttaaaatgggaaaaaaatgg
ccaagagctgcctcagaagcatgataagcacctggtgctccaggatttctcggaagtcgaggacagtggctactacg
tctgctacacaccagcctcaaataaaaacacgtacttgtacctgaaagctcgagtgtgtgagtactgtgtggaggtgga
cctgacagcagtagccataatcatcattgttgacatctgtatcactctgggcttgctgatggtcatttattactggagcaag
aataggaaggccaaggccaagcctgtgacccgaggaaccggtgctggtagcaggcccagagggcaaaacaag
gagcggccaccacctgttcccaacccagactatgagcccatccgcaaaggccagcgggacctgtattctggcctga
atcagagagcagtcGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAG
AATCCTGGCCCAatggaacacagcgggattctggctagtctgatactgattgctgttctcccccaagggagcc
ccttcaaggtacaagtgaccgaatatgaggacaaagtatttgtgacctgcaataccagcgtcatgcatctagatggaa
cggtggaaggatggtttgcaaagaataaaacactcaacttgggcaaaggcgttctggacccacgagggatatatctg
tgtaatgggacagagcagctggcaaaggtggtgtcttctgtgcaagtccattaccgaatgtgccagaactgtgtggag
ctagactcgggcaccatggctggtgtcatcttcattgacctcatcgcaactctgctcctggctttgggcgtctactgctttgc
aggacatgagaccggaaggccttctggggctgctgaggttcaagcactgctgaagaatgagcagctgtatcagcctc
ttcgagatcgtgaagatacccagtacagccgtcttggagggaactggccccggaacaagaaatctCAATGTAC
TAACTACGCTTTGTTGAAACTCGCTGGCGATGTTGAAAGTAACCCCGGTCCTat
ggagcagaggaagggtctggctggcctcttcctggtgatctctcttcttcaaggcactgtagcccagacaaataaagc
aaagaatttggtacaagtggatggcagccgaggagacggttctgtacttctgacttgtggcttgactgacaagactatc
aagtggcttaaagacgggagcataataagtcctctaaatgcaactaaaaacacatggaatctgggcaacaatgcca
aagaccctcgaggcacgtatcagtgtcaaggagcaaaggagacatcaaaccccctgcaagtgtattacagaatgtg
tgaaaactgcattgagctaaacataggcaccatatccggctttatcttcgctgaggtcatcagcatcttcttccttgctcttg
gtgtatatctcattgcgggacaggatggagttcgccagtcaagagcttcagacaagcagactctgttgcaaaatgaac
140
agctgtaccagcccctcaaggaccgggaatatgaccagtacagccatctccaaggaaaccaactgaggaagaag
qtcqac
141
Appendix II: N0T1— Sal1-IRES GFP- LPRE pMP71
Not1 (red)
Cloning site underlined 
Sail (blue)
GCGGCCGC GTCGACCTC GAGATCCGCC CCTCTCCCTC
CCCCCCCCCT
AACGTTACTG GCCGAAGCCG CTTGGAATAA GGCCGGTGTG CGTTTGTCTA 
TATGTTATTT TCCACCATAT TGCCGTCTTT TGGCAATGTG AGGGCCCGGA 
AACCTGGCCC TGTCTTCTTG ACGAGCATTC CTAGGGGTCT TTCCCCTCTC 
GCCAAAGGAA TGCAAGGTCT GTTGAATGTC GTGAAGGAAG CAGTTCCTCT 
GGAAGCTTCT TGAAGACAAA CAACGTCTGT AGCGACCCTT TGCAGGCAGC 
GGAACCCCCC ACCTGGCGAC AGGTGCCTCT GCGGCCAAAA GCCACGTGTA 
TAAGATACAC CTGCAAAGGC GGCACAACCC CAGTGCCACG TTGTGAGTTG 
GATAGTTGTG GAAAGAGTCA AATGGCTCTC CTCAAGCGTA TTCAACAAGG 
GGCTGAAGGA TGCCCAGAAG GTACCCCATT GTATGGGATC TGATCTGGGG 
CCTCGGTGCA CATGCTTTAC ATGTGTTTAG TCGAGGTTAA AAAAACGTCT 
AGGCCCCCCG AACCACGGGG ACGTGGTTTT CCTTTGAAAA ACACGATGAT 
AATATGGCCA CAACCATGGT GAGCAAGGGC GAGGAGCTGT TCACCGGGGT 
GGTGCCCATC CTGGTCGAGC TGGACGGCGA CGTAAACGGC CACAAGTTCA 
GCGTGTCCGG CGAGGGCGAG GGCGATGCCA CCTACGGCAA GCTGACCCTG 
AAGTTCATCT GCACCACCGG CAAGCTGCCC GTGCCCTGGC CCACCCTCGT 
GACCACCCTG ACCTACGGCG TGCAGTGCTT CAGCCGCTAC CCCGACCACA 
TGAAGCAGCA CGACTTCTTC AAGTCCGCCA TGCCCGAAGG CTACGTCCAG 
GAGCGCACCA TCTTCTTCAA GGACGACGGC AACTACAAGA CCCGCGCCGA 
GGTGAAGTTC GAGGGCGACA CCCTGGTGAA CCGCATCGAG CTGAAGGGCA 
TCGACTTCAA GGAGGACGGC AACATCCTGG GGCACAAGCT GGAGTACAAC 
TACAACAGCC ACAACGTCTA TATCATGGCC GACAAGCAGA AGAACGGCAT 
CAAGGTGAAC TTCAAGATCC GCCACAACAT CGAGGACGGC AGCGTGCAGC 
TCGCCGACCA CTACCAGCAG AACACCCCCA TCGGCGACGG CCCCGTGCTG 
CTGCCCGACA ACCACTACCT GAGCACCCAG TCCGCCCTGA GCAAAGACCC 
CAACGAGAAG CGCGATCACA TGGTCCTGCT GGAGTTCGTG ACCGCCGCCG 
GGATCACTCT CGGCATGGAC GAGCTGTACA GAATTCGAGC ATCTTACCGC 
CATTTATTCC CATATTTGTT CTGTTTTTCT TGATTTGGGT ATACATTTAA 
ATGTTAATAA AACAAAATGG TGGGGCAATC ATTTACATTT TATGGGATAT 
GTAATTACTA GTTCAGGTGT ATTGCCACAA GACAAACATG TTAAGAAACT 
TTCCCGTTAT TTACGCTCTG TTCCTGTTAA TCAACCTCTG GATTACAAAA 
TTTGTGAAAG ATTGACTGAT ATTCTTAACT ATGTTGCTCC TTTTACGCTG 
TGTGGATATG CTGCTTTAAT GCCTCTGTAT CATGCTATTG CTTCCCGTAC 
GGCTTTCGTT TTCTCCTCCT TGTATAAATC CTGGTTGCTG TCTCTTTATG 
AGGAGTTGTG GCCCGTTGTC CGTCAACGTG GCGTGGTGTG CTCTGTGTTT 
GCTGACGCAA CCCCCACTGG CTGGGGCATT GCCACCACCT GTCAACTCCT 
TTCTGGGACT TTCGCTTTCC CCCTCCCGAT CGCCACGGCA GAACTCATCG 
CCGCCTGCCT TGCCCGCTGC TGGACAGGGG CTAGGTTGCT GGGCACTGAT 
AATTCCGTGG TGTTGTCGGG GAAGCTGACG TCCTTTCCAT GGCTGCTCGC 
CTGTGTTGCC AACTGGATCC TGCGCGGGAC GTCCTTCTGC TACGTCCCTT 
CGGCTCTCAA TCCAGCGGAC CTCCCTTCCC GAGGCCTTCT GCCGGTTCTG 
CGGCCTCTCC CGCGTCTTCG CTTTCGGCCT CCGACGAGTC GGATCTCCCT 
TTGGGCCGCC TCCCCGCCTG TTTCGCCTCG GCGTCCGGTC CGTGTTGCTT 
GGTCGTCACC TGTGCAGAAT TGCGAACCAT GGATTCCACC GTGAACTTTG
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g t c t t t c a t t
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CTGCATTAAT 
GCGCTCTTCC 
TGCGGCGAGC 
GAATCAGGGG 
GGCCAGGAAC 
GCCCCCCTGA 
AACCCGACAG 
CGTGCGCTCT 
TTCTCCCTTC 
CTCAGTTCGG 
CCCCGTTCAG 
CCAACCCGGT 
AGGAT TAGCA 
GTGGCCTAAC 
TGCTGAAGCC 
AAACAAACCA 
TACGCGCAGA 
GGTCTGACGC 
AGATTATCAA 
TTTTAAATCA 
AATGCTTAAT 
TCCATAGTTG 
CTTACCATCT 
CGGCTCCAGA 
AGAAGTGGTC 
CCGGGAAGCT 
TTGCCATTGC 
TCATTCAGCT 
GTTGTGCAAA 
GTAAGTTGGC 
TCTCTTACTG
TGCCAAGAAT 
ATTTCTATTA 
GATATTATGA 
CTAACACGAG 
AGGGGGGAAT 
AGCCATTTTG 
AGATCAAGGT 
TCTGTGGTAA 
AGCAGAATAT 
GCTCAGGGCC 
TTTCTAGAGA 
ACCCTGTGCC 
CGCGCGCTTC 
CGGCGCGCCA 
CAATAAAGC C 
GGGAGGGTCT 
CTCGAGAGCT 
GTTATCCGCT 
AAAGCCTGGG 
CTCACTGCCC 
GAATCGGCCA 
GCTTCCTCGC 
GGTATCAGCT 
ATAACGCAGG 
CGTAAAAAGG 
CGAGCATCAC 
GACTATAAAG 
CCTGTTCCGA 
GGGAAGCGTG 
TGTAGGTCGT 
CCCGACCGCT 
AAGACACGAC 
GAGCGAGGTA 
TACGGCTACA 
AGTTACCTTC 
CCGCTGGTAG 
AAAAAAGGAT 
TCAGTGGAAC 
AAAGGATCTT 
AT C TAAAGTA 
CAGTGAGGCA 
CCTGACTCCC 
GGCCCCAGTG 
TTTATCAGCA 
CTGCAACTTT 
AGAGTAAGTA 
TGCTGGCATC 
CCGGTTCCCA 
AAAGCGGTTA 
CGCAGTGTTA 
TCATGCCATC
TCGGATCCAA 
AAGGTTCCTT 
AGGGCCTTGA 
CCATAGATAG 
GAAAGACCCC 
CAAGGCATGG 
TAGGAACAGA 
GCAGTTCCTG 
GGGCCAAACA 
AAGAACAGAT 
ACCATCAGAT 
TTATTTGAAC 
TGCTCCCCGA 
GTCCTCCGAT 
TCTTGCTGTT 
CCTCAGATTG 
TTGGCGTAAT 
CACAATTCCA 
GTGCCTAATG 
GCTTTCCAGT 
ACGCGCGGGG 
TCACTGACTC 
CACTCAAAGG 
AAAGAACATG 
CCGCGTTGCT 
AAAAATCGAC 
ATACCAGGCG 
CCCTGCCGCT 
GCGCTTTCTC 
TCGCTCCAAG 
GCGCCTTATC 
TTATCGCCAC 
TGTAGGCGGT 
CTAGAAGGAC 
GGAAAAAGAG 
CGGTGGTTTT 
CTCAAGAAGA 
GAAAACTCAC 
CACCTAGATC 
TATATGAGTA 
CCTATCTCAG 
CGTCGTGTAG 
CTGCAATGAT 
ATAAACCAGC 
ATCCGCCTCC 
GTTCGCCAGT 
GTGGTGTCAC 
ACGATCAAGG 
GCTCCTTCGG 
TCACTCATGG 
CGTAAGATGC
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TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT 
GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC 
CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG 
CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC 
CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT 
CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG 
GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG 
AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA 
TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG 
CCACCTGACG TCTAAGAAAC CATTATTATC ATGACATTAA CCTATAAAAA 
TAGGCGTATC ACGAGGCCCT TTCGTCTTCA AGCTGCCTCG CGCGTTTCGG 
TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG 
CTTGTCTGTA AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA 
GCGGGTGTTG GCGGGTGTCG GGGCGCAGCC ATGACCCAGT CACGTAGCGA 
TAGTTACTAT GCGGCATCAG AGCAGATTGT ACTGAGAGTG CACCATATGC 
GGTGTGAAAT ACCGCACAGA TGCGTAAGGA GAAAATACCG CATCAGGCGC 
CATTCGCCAT TCAGGCTGCG CAACTGTTGG GAAGGGCGAT CGGTGCGGGC 
CTCTTCGCTA TTACGCCAGC TGGCGAAAGG GGGATGTGCT GCAAGGCGAT 
TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG TAAAACGACG 
GCCAGTGAAT TAGTACTCTA GCTTAAGTAA GCCATTTTGC AAGGCATGGA 
AAAATACATA ACTGAGAATA GAGAAGTTCA GATCAAGGTTAG GAACAGAGAG 
ACAGGAGAAT ATGGGCCAAA CAGGATATCT
GTGGTAAGCA GTTCCTGCCC CGGCTCAGGG CCAAGAACAG TTGGAACAGC 
AGAATATGGG CCAAACAGGA TATCTGTGGT AAGCAGTTCC TGCCCCGGCT 
CAGGGCCAAG AACAGATGGT CCCCAGATGC GGTCCCGCCC TCAGCAGTTT 
CTAGAGAACC ATCAGATGTT TCCAGGGTGC CCCAAGGACC TGAAATGACC 
CTGTGCCTTA TTTGAACTAA CCAATCAGTT CGCTTCTCGC TTCTGTTCGC 
GCGCTTCTGC TCCCCGAGCT CAATAAAAGA GCCCACAACC CCTCACTCGG 
CGCGCCAGTC CTCCGATTGA CTGCGTCGCC CGGGTACCCG TATTCCCAAT 
AAAGCCTCTT GCTGTTTGCA TCCGAATCGT GGACTCGCTG ATCCTTGGGA 
GGGTCTCCTC AGATTGATTG ACTGCCCACC TCGGGGGTCT TTCATTTGGA 
GGTTCCACCG AGATTTGGAG ACCCCTGCCC AGGGACCACC GACCCCCCCG 
CCGGGAGGTA AGCTGGCCAG CGGTCGTTTC GTGTCTGTCT CTGTCTTTGG 
GCGTGTTTGT GCCGGCATCT AATGTTTGCG CCTGCGTCTG TACTAGTTGG 
CTAACTAGAT CTGTATCTGG CGGTCCCGCG GAAGAACTGA CGAGTTCGTA 
TTCCCGGCCG CAGCCCCTGG GAGACGTCCC AGCGGCCTCG GGGGCCCGTT 
TTGTGGCCCA TTCTGTATCA GTTAACCTAC CCGAGTCGGA CTTTTTGGAG 
CTCCGCCACT GTCCGAGGGG TACGTGGCTT TGTTGGGGGA CGAGAGACAG 
AGACACTTCC CGCCCCCGTC TGAATTTTTG CTTTCGGTTT TACGCCGAAA 
CCGCGCCGCG CGTCTTGTCT GCTGCAGCAT CGTTCTGTGT TGTCTCTGTC 
TGACTGTGTT TCTGTATTTG TCTGAAAATT AGCTCGACAA AGTTAAGTAA 
TAGTCCCTCT CTCCAAGCTC ACTTACAG
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